

ACC/AHA PRACTICE GUIDELINES

ACC/AHA Guidelines for Ambulatory Electrocardiography

A Report of the American College of Cardiology/American
Heart Association Task Force on Practice Guidelines
(Committee to Revise the Guidelines for Ambulatory Electrocardiography)
*Developed in Collaboration with the
North American Society for Pacing and Electrophysiology*

COMMITTEE MEMBERS

MICHAEL H. CRAWFORD, MD, FACC, *Chair*

STEVEN J. BERNSTEIN, MD, MPH, FACP
PRAKASH C. DEEDWANIA, MD, MBBS, FACC
JOHN P. DiMARCO, MD, PhD, FACC
KEVIN J. FERRICK, MD, FACC
ARTHUR GARSON, JR, MD, MPH, FACC

LEE A. GREEN, MD, MPH, FAFAP
H. LEON GREENE, MD, FACC
MICHAEL J. SILKA, MD, FACC
PETER H. STONE, MD, FACC
CYNTHIA M. TRACY, MD, FACC

TASK FORCE MEMBERS

RAYMOND J. GIBBONS, MD, FACC, *Chair*

JOSEPH S. ALPERT, MD, FACC
KIM A. EAGLE, MD, FACC
TIMOTHY J. GARDNER, MD, FACC
ARTHUR GARSON, JR, MD, MPH, FACC

GABRIEL GREGORATOS, MD, FACC
RICHARD O. RUSSELL, MD, FACC
THOMAS J. RYAN, MD, FACC
SIDNEY C. SMITH, JR, MD, FACC

“ACC/AHA Guidelines for Ambulatory Electrocardiography: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography)” was approved by the American College of Cardiology Board of Trustees in June 1999 and by the American Heart Association Science Advisory and Coordinating Committee in June 1999.

The American College of Cardiology and the American Heart Association request that the following citation format be used when citing this document: Crawford MH, Bernstein SJ, Deedwania PC, DiMarco JP, Ferrick KJ, Garson A Jr, Green LA, Greene HL, Silka MJ, Stone PH, Tracy CM. ACC/AHA guidelines for ambulatory electrocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the Guidelines for Ambulatory Electrocardiography). *J Am Coll Cardiol* 1999;34:912–48.

This document is available on the worldwide websites of the American College of Cardiology (www.acc.org) and the American Heart Association (www.americanheart.org). Reprints of this document (the complete guidelines) are available for \$5 each by calling 800-253-4636 (US only) or writing the American College of Cardiology, Resource Center, 9111 Old Georgetown Road, Bethesda, MD 20814-1699. Ask for reprint No. 71-0172. To obtain a reprint of the shorter version (executive summary and recommendations) published in the August 24, 1999, issue of *Circulation*, ask for reprint No. 71-0171. To purchase additional reprints (specify version and reprint number): up to 999 copies, call 800-611-6083 (US only) or fax 413-665-2671; 1000 or more copies, call 214-706-1466, fax 214-691-6342, or e-mail pubauth@heart.org.

TABLE OF CONTENTS

Preamble.....	913
I. Introduction.....	913
II. AECG Equipment	914
A. Continuous Recorders	915
B. Methods of Electrode Preparation and Lead Systems Used	916
C. Variability of Arrhythmias and Ischemia and Optimal Duration of Recording.....	916
D. Intermittent Recorders.....	916
E. AECG Recording Capabilities Associated With Pacemakers and ICDs	917
F. Playback Systems and Methods of Analysis	917
1. Arrhythmia Analysis	917
2. Ischemia Analysis.....	917
G. Emerging Technologies.....	918
III. Heart Rate Variability.....	918

- A. General Considerations918
- B. Technical Requirements for Recording and Analysis918
 - 1. Duration of Recording918
 - 2. Artifact and Arrhythmias919
- C. Day-to-Day Variability.....919
- IV. Assessment of Symptoms That May Be Related to Disturbances of Heart Rhythm920
 - A. Symptomatic Arrhythmias.....920
 - B. Selection of Recording Technique.....920
 - C. Specific Symptoms.....921
 - 1. Syncope921
 - 2. Palpitation.....921
 - 3. Other Symptoms.....921
- V. Assessment of Risk in Patients Without Symptoms of Arrhythmias.....922
 - A. After Myocardial Infarction922
 - B. Congestive Heart Failure.....924
 - C. Hypertrophic Cardiomyopathy.....928
 - D. Valvular Heart Disease.....928
 - E. Diabetic Neuropathy.....928
 - F. Hemodialysis Patients.....928
 - G. Systemic Hypertension.....928
 - H. Preoperative and Postoperative Patients.....929
 - I. Screening in Other Patients.....929
 - J. Monitoring Pharmacological Management929
 - K. Summary929
- VI. Efficacy of Antiarrhythmic Therapy929
- VII. Assessment of Pacemaker and ICD Function931
- VIII. Monitoring for Myocardial Ischemia932
 - A. General Considerations932
 - B. Prevalence and Predictive Value.....933
 - C. Role in Therapeutic Evaluation935
 - D. Limitations935
- IX. Pediatric Patients.....936
 - A. Evaluation of Symptoms.....937
 - B. Evaluation of the Patient With Known Cardiovascular Disease937
 - C. Other Medical Conditions938
 - D. Evaluation After Therapy or Intervention.....938
- References.....939

PREAMBLE

It is important that the medical profession play a significant role in critically evaluating the use of diagnostic procedures and therapies in the management or prevention of disease states. Rigorous and expert analysis of the available data documenting relative benefits and risks of those procedures and therapies can produce helpful guidelines that improve the effectiveness of care, optimize patient outcomes, and affect the overall cost of care favorably by focusing resources on the most effective strategies.

The American College of Cardiology (ACC) and the American Heart Association (AHA) have jointly engaged in the production of such guidelines in the area of cardiovascular disease since 1980. This effort is directed by the

ACC/AHA Task Force on Practice Guidelines. Its charge is to develop and revise practice guidelines for important cardiovascular diseases and procedures. Experts in the subject under consideration are selected from both organizations to examine subject-specific data and write guidelines. The process includes additional representatives from other medical practitioner and specialty groups where appropriate. Writing groups are specifically charged to perform a formal literature review, weigh the strength of evidence for or against a particular treatment or procedure, and include estimates of expected health outcomes where data exist. Patient-specific modifiers, comorbidities, and issues of patient preference that might influence the choice of particular tests or therapies are considered as well as frequency of follow-up and cost-effectiveness.

These practice guidelines are intended to assist physicians in clinical decision making by describing a range of generally acceptable approaches for the diagnosis, management, or prevention of specific diseases or conditions. These guidelines attempt to define practices that meet the needs of most patients in most circumstances. The ultimate judgment regarding care of a particular patient must be made by the physician and patient in light of all of the circumstances presented by that patient.

The executive summary and recommendations are published in the August 24, 1999, issue of *Circulation*. The full text is published in the *Journal of the American College of Cardiology*. Reprints of both the full text and the executive summary and recommendations are available from both organizations.

These guidelines have been officially endorsed by the North American Society for Pacing and Electrophysiology.

*Raymond J. Gibbons, MD, FACC
Chair, ACC/AHA Task Force on Practice Guidelines*

I. INTRODUCTION

The ACC/AHA Guidelines for Ambulatory Electrocardiography (AECG) were last published in 1989 (1). Since then, there have been improvements in solid-state digital technology that have expanded transtelephonic transmission of ECG data and enhanced the accuracy of software-based analysis systems. These advances, in addition to better signal quality and greater computer arrhythmia interpretation capabilities, have opened new potential uses for AECG. Despite these advances, a true automated analysis system has not been perfected and technician/physician participation is still essential.

Traditional uses of AECG for arrhythmia detection have expanded as the result of increased use of multichannel and telemetered signals. The clinical application of arrhythmia monitoring to assess drug and device efficacy has been further defined by new studies. The analysis of transient ST-segment deviation remains controversial, but considerably more data are now available, especially about the prognostic value of detecting asymptomatic ischemia. Heart

rate variability (HRV) analysis has shown promise for predicting mortality rates in high-risk cardiac patients. Technological advances with long-term event recorders have permitted the self-activation of AECG monitors, but the reliability of fully automatic recording systems has not been established for routine clinical use. Rapid technological advances portend further improvements in equipment in the near future.

These guidelines focus on the use of AECG to aid clinical decision making. Thus, emphasis will be placed on the most common clinical uses of the technique. Evaluation of the clinical utility of a diagnostic test is more difficult than assessing the efficacy of a therapeutic intervention because diagnostic tests do not usually have the same direct impact on patient outcomes (2). In considering the use of AECG in individual patients, the following factors were important:

1. The technical capacity of the available equipment used for performing the study and the quality, expertise, and experience of the professional and technical staff necessary to perform and interpret the study
2. The diagnostic accuracy of the technique
3. The accuracy of the technique as compared with other diagnostic procedures
4. The effect of positive or negative results on subsequent clinical decision making
5. The influence of the technique on health-related outcomes.

The usefulness of AECG techniques in specific clinical situations is indicated by means of the following classification:

- Class I:** Conditions for which there is evidence and/or general agreement that a given procedure or treatment is useful and effective
- Class II:** Conditions for which there is conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of a procedure or treatment
- Class IIa:** Weight of evidence/opinion is in favor of usefulness/efficacy
- Class IIb:** Usefulness/efficacy is less well established by evidence/opinion
- Class III:** Conditions for which there is evidence and/or general agreement that the procedure/treatment is not useful/effective, and in some cases may be harmful

This report includes brief descriptions of instrumentation and systems and reviews the use of AECG for 1) arrhythmia detection; 2) prognosis; 3) efficacy of antiarrhythmic therapy; 4) assessing pacemaker function and implantable cardioverter-defibrillator (ICD) function; 5) detecting myocardial ischemia; and 6) use in children. Tables appear in each section that summarize the recommendations for that particular application.

The Committee reviewed and compiled pertinent published reports by computerized and hand searches, excluding abstracts, and the recommendations made are based on these reports. Data tables are presented where multiple reports are available, but formal meta-analyses were not performed because of the nature of the available data and cost constraints. When few or no data existed, this is identified in the text, and recommendations are based on committee consensus. A complete list of the multiple publications on AECG is beyond the scope of this communication, and only selected references are included, emphasizing new data since 1989. Finally, although cost considerations are important, there were insufficient data to present formal cost-effectiveness analyses. However, cost was considered in general terms for the recommendations.

The Committee membership consisted of acknowledged experts in AECG, general cardiologists, cardiologists with expertise in arrhythmias and pacing, 1 family practitioner, and 1 general internist. Both the academic and private practice sectors are represented. No member reported a conflict of interest bearing on committee participation. The guidelines will be considered current unless the Task Force publishes revisions or a withdrawal.

II. AECG EQUIPMENT

Since the introduction of portable devices to record the ECG in 1957 by Dr Norman Holter, there have been major advances in recording and playback methodologies. The widespread and inexpensive availability of personal computers and workstations has allowed for the development of extremely sophisticated and automated signal processing algorithms. Current AECG equipment provides for the detection and analysis of arrhythmias and ST-segment deviation as well as more sophisticated analyses of R-R intervals, QRS-T morphology including late potentials, Q-T dispersion, and T-wave alternans.

There are 2 categories of AECG recorders. Continuous recorders, typically used for 24 to 48 hours, investigate symptoms or ECG events that are likely to occur within that time frame. Intermittent recorders may be used for long periods of time (weeks to months) to provide briefer, intermittent recordings to investigate events that occur infrequently. Two basic types of intermittent recorders have slightly different utility. A loop recorder, which is worn continuously, may be particularly useful if symptoms are quite brief or if symptoms include only very brief incapacitation such that the patient can still activate the recorder immediately afterward and record the stored ECG. It is sometimes possible for a family member to activate the recorder if the patient actually loses consciousness. However, even a loop recorder with a long memory may not be useful if loss of consciousness includes prolonged disorientation on awakening that would prohibit the patient from activating the device. Newer loop recorders can be implanted under the skin for long-term recordings, which may

be particularly useful for patients with infrequent symptoms. Another type of intermittent recorder is the event recorder, which is attached by the patient and activated after the onset of symptoms. It is not useful for arrhythmias that cause serious symptoms such as loss of consciousness or near loss of consciousness because these devices take time to find, apply, and activate. They are more useful for infrequent, less serious but sustained symptoms that are not incapacitating. For this review, equipment will be described for the recorders first and then for the playback systems. Only selected technical details are presented in this review. A more complete description of the technical requirements for AECG equipment can be found in the 1994 American National Standard developed by the Association for the Advancement of Medical Instrumentation (3).

A. Continuous Recorders

Conventional AECG recorders typically are small, light-weight devices (8 to 16 oz) that record 2 or 3 bipolar leads. They contain a quartz digital clock and a separate recording track to keep time. They are generally powered by a 9-V disposable alkaline battery and a calibration signal automatically inserted when the device is energized. A patient-activated event marker is conveniently placed on the device for the patient to indicate the presence of symptoms or to note an event. The frequency response of the recording and playback system should be reasonably flat, from 0.67 to 40 Hz.

The conventional format for recording has been magnetic cassette-type tape. Tape speed typically is 1 mm/s, and speed is kept constant by an optical speed sensor on the flywheel and a crystal controlled phase locked loop. This technology has been the standard for many years and has the advantage of being inexpensive and providing a permanent record of all electrical activity throughout the recording period. This format allows for playback and interrogation of the entire recording period (so-called "full disclosure"). It is adequate to detect abnormalities of rhythm or conduction, but it may be limited for recording low-frequency signals such as the ST segment. An inadequate low-frequency response or marked phase shift from the higher-frequency QRS signal can lead to artifactual distortion of the ST segment that may be incorrectly interpreted as ischemic, particularly using some amplitude-modulated (AM) systems (4). More recent AM systems have been designed with improved low-frequency recording and playback characteristics and have been documented to record accurately ST-segment deviation (5) and even T-wave alternans (6). The frequency-modulated (FM) systems avoid this bias because they can be designed with an ideal low-frequency response without a low-frequency "boost" and are less prone to phase shift (4). However, FM systems are not as widely available, are more costly, and are subject to more baseline "noise" than AM systems (4). Regardless of whether AM or FM recording techniques are used, the tape itself may stretch and consequently distort the electrical signal.

Rapidly evolving technologies now allow for direct recording of the ECG signal in a digital format by use of solid-state recording devices. The direct digital recording avoids all of the biases introduced by the mechanical features of tape recording devices and the problems associated with recording data in an analog format, which requires analog-to-digital conversion before analysis. ECG signals can be recorded at up to 1000 samples per second, which allows for the extremely accurate reproduction of the ECG signal necessary to perform signal averaging and other sophisticated ECG analyses. These solid-state recordings can be analyzed immediately and rapidly, and some recorders are now equipped with microprocessors that can provide "on-line analysis" of the QRS-T complex as it is acquired. If specific abnormalities are detected, such as ST-segment deviation, immediate feedback can be provided to the patient. The solid-state format also provides for ready electronic data transfer to a central analysis facility. Limitations of this technology include its expense, the limited storage capacity of digital data, and, in the case of on-line analysis, reliance on a computer algorithm to identify abnormalities accurately. A 24-hour recording includes approximately 100,000 QRS-T complexes and requires almost 20 megabytes of storage per channel. Problems of storage capacity have been approached with 2 techniques of "compressing" the recorded data: 1) "lossy" compression of QRS-T complexes with very high compression ratios and 2) "loss-less" compression combined with enhanced storage capacity. Much of the reluctance of physicians to use solid-state methodologies in the past has been due to lack of faith in the "lossy" compression methods because their accuracy is dependent on the ability of the microprocessor to distinguish important physiological abnormalities from artifact or a wandering baseline. Confirmation of the "decisions" by the microprocessor cannot be made because the primary data are not recorded in their entirety and cannot be retrieved nor reproduced without error (ie, non-full disclosure). Because it is essential that representative ECG complexes from all ischemic episodes or arrhythmias be confirmed by an experienced technician or physician, the lack of full disclosure may limit the reliability of the compressed storage method (7,8). Accuracy of the on-line interpretations also may be different for ischemia versus arrhythmia analyses (9). The clinical usage of "lossy" compressed recordings and on-line interpretations is limited. There are insufficient data comparing analyses based on full-disclosure recordings versus "lossy" compressed recordings that are interpreted on-line to determine the suitability of the high-ratio compression methodologies for widespread use.

The newer technologies of enhanced storage capacity allow for all of the technical advantages of solid-state recording and now allow "full disclosure" by using loss-less compression methods, which reduce the amount of storage required by a factor of 3 to 5 but still permit reconstruction of the waveform with no loss of information. The storage

methodologies available include a flash memory card or a portable hard drive. Flash cards are very small, compact storage devices, which are about the size of a credit card and have the capacity to store 20 to 40 megabytes of data. The flash cards are removed from the recording device once the recording is completed and are inserted into a separate device where the data can be played back and analyzed or the data can be transmitted electronically to another location for analysis. Miniature hard drives utilize the same technology used in laptop computers and can store more than 100 megabytes of data. Unlike flash cards, the hard drives are not removed from the recorder but the data are downloaded to another storage device or electronically transferred.

B. Methods of Electrode Preparation and Lead Systems Used

The skin over the electrode area should be shaved, if necessary, gently abraded with emery tape, and thoroughly cleansed with an alcohol swab. To optimize recordings of the low-frequency ST segment, skin resistance may be measured with an impedance meter once the electrodes are applied. The measured resistance between electrodes should be ≤ 5 k Ω and preferably ≤ 2 k Ω .

Most recorders utilize 5 or 7 electrodes attached to the chest, which record the signal from 2 or 3 bipolar leads onto 2 or 3 channels. The third channel may be dedicated to recording pacemaker activity. A variety of bipolar lead configurations are used, the most common being a chest modified V_5 (CM_5), a chest modified V_3 (CM_3), and a modified inferior lead. If a patient undergoing AECG monitoring for ischemia has had an exercise test with ischemic changes, the AECG lead configuration should mimic those leads with the greatest ST-segment change during exercise. A test cable can be connected from the recorder to a standard ECG machine when the device is attached to the patient to verify amplitude, rate, and morphology of waveforms that will be recorded. Once the leads have been applied, before the patient leaves the laboratory, supervised recordings should be made with the patient in the standing, sitting, right and left lateral decubitus, and supine positions to ensure that artifactual ST-segment deviation does not occur.

In a recent study of simultaneous recordings of a 3-lead AECG and a conventional 12-lead ECG recording during an exercise treadmill test (10), CM_5 was the single lead with the highest sensitivity (89%) in detecting myocardial ischemia. The addition of CM_3 to CM_5 increased sensitivity to 91%, and the addition of an inferior lead to CM_5 increased the sensitivity to 94%, particularly improving detection of isolated inferior ischemia. The combination of all 3 AECG leads had a sensitivity of 96%, only 2% more than the best combination of 2 leads (CM_5 plus an inferior lead). Thus, routine identification of ischemic ST-segment deviation may only require 2 leads. Use of an inverse Nehb J lead, in which the positive electrode is placed on the left posterior

axillary line, may enhance sensitivity to detect ischemia (11). Some new AECG monitor systems can record a true 12-lead ECG, whereas others derive a 12-lead ECG from 3-lead data through the use of a mathematical transform.

C. Variability of Arrhythmias and Ischemia and Optimal Duration of Recording

The day-to-day variability of the frequency of arrhythmias or ST-segment deviation is substantial (12-22). Most arrhythmia studies use a 24-hour recording period, although yield may be increased slightly with longer recordings or repeated recordings (23). Major reductions in arrhythmia frequency are necessary to prove a treatment effect. To ensure that a change is due to the treatment effect and not to spontaneous variability, a 65% to 95% reduction in arrhythmia frequency after an intervention is necessary (12).

The variability of the frequency, duration, and depth of ischemic ST-segment depression is also marked (24-28). Because most ischemic episodes during routine daily activities are related to increases in heart rate (29), the variability of ischemia between recording sessions may be due to day-to-day variability of physical or emotional activities (30). It is therefore essential to encourage similar daily activities at the time of AECG recording. The optimal and most feasible duration of recording to detect and quantify ischemia episodes is probably 48 hours (25). Most patients are quite comfortable wearing the recorder for 48 hours.

The variability of AECG ischemia strongly influences clinical trial design to identify the efficacy of a therapeutic intervention (26,28). For example, a 75% reduction in the number of ischemic episodes would be necessary to achieve statistical significance within an individual patient monitored for 48 hours before and after an intervention (28). Families of relations have been calculated for sample size estimates and statistical power for intervention trials (26,28).

D. Intermittent Recorders

These devices, which are also termed "event recorders," include those that record and store only a brief period of ECG activity when activated by the patient in response to symptoms and those that record the ECG in a continuous manner but store only a brief period of ECG recording (eg, 5 to 300 seconds) in memory when the event marker is activated by the patient at the time of a symptom (loop recorder). These devices often use solid-state memory and can transfer data readily over conventional telephone lines. These recorders can be used for prolonged periods of time (many weeks) to identify infrequently occurring arrhythmias or symptoms that would not be detected with a conventional 24-hour AECG recording. Newer loop recorders can be implanted for longer-term monitoring. An event recorder relies on rapid placement of electrodes, such as paddles connected to the recorder or a wrist bracelet, to record the ECG at the time of the symptom. Loop recorders use continuously worn electrodes. The recorded signal can be

transmitted to a receiving station or may be saved in memory and transferred at a later time to a central analysis facility.

Intermittent recorders have the advantage of being small and light, easy to use, and can be programmed to record many short episodes during an extended period of time (in most cases up to 30 days). Single-, 2-, 3-, and reconstructed 12-lead formats are available.

E. AECG Recording Capabilities Associated With Pacemakers and ICDs

Most current ICDs continually monitor the intracardiac electrogram and store in memory a summary of tachycardia and bradycardia episodes as well as a brief electrogram meeting prespecified criteria preceding and following each therapeutic discharge.

Intracardiac electrograms may be recorded from a variety of leads and electrode pairs, depending on the equipment used (31). These devices can store only a limited number or duration of recordings (32). Many pacemakers have the capability to calculate heart rate for a selected period of time. See Section VII for further description of recording capabilities of current pacemakers and ICD devices.

F. Playback Systems and Methods of Analysis

Most current playback systems use generic computer hardware platforms running proprietary software protocols for data analysis and report generation. Facsimile, modem, network, and Internet integration allow for rapid distribution of AECG data and analyses throughout a healthcare system. Signals recorded in analog format (ie, magnetic tape) are digitized at either a rate of 128 or 256 samples per second for subsequent analysis. The clock track on the tape can compensate for variations in tape speed by a phase lock loop circuit. The resolution is usually at least 8 bits and the sampling rate is nominally 128 samples per second. The signal amplitude can be adjusted by the technician on the basis of the calibration signal recorded automatically at the initiation of each recording. Tape playback and scanning options include rapid playback with either superimposition (up to 1000 times real time) or page-type displays.

It is critical that each classification of arrhythmia morphology and each ischemic episode be reviewed by an experienced technician or physician to ensure accurate diagnosis because AECG recordings during routine daily activities frequently have periods of motion artifact or baseline wander that may distort the ST-segment or QRS morphology. The presence of artifacts can be minimized by good skin preparation, use of high-quality ECG electrodes and monitoring leads, lead placement secured by loops of the electrode cable, and awareness of ST-segment deviation caused by changes in body position. Although the identification of ischemia made by the computer algorithm alone may be helpful, the interpretations are frequently found to be incorrect when assessed by an experienced observer. Overreading is essential. In an experienced laboratory, the

interobserver and intraobserver agreement for the presence and characterizations of ischemic episodes should be high. Preliminary studies suggest that there may be differences in interpretation of ST-segment activity among different laboratories. Much more investigation concerning the uniformity of interpretations of ischemic ST-segment deviation is necessary before widespread application of ischemia monitoring is feasible and reliable. Interobserver and intraobserver agreement is excellent for categorization of arrhythmias, but discrepancies of 10% to 25% in total ventricular arrhythmia counts for the same recording may occur if frequent or complex arrhythmias are present (33).

1. Arrhythmia Analysis. Each beat is classified as normal, ventricular ectopic, supraventricular ectopic, paced, other, or unknown, and a template for each type of abnormality is created. The computer tabulates the number of ectopic beats in each template. Summary data describing the frequency of atrial and ventricular arrhythmias are displayed typically in both tabular and graphical formats. The system automatically stores strips of significant arrhythmia events detected as well as patient events and entered diary notation times.

2. Ischemia Analysis. The QRS-T morphology must be carefully scrutinized to ensure that it is suitable for interpretation to identify ischemic changes (34). The rhythm should be normal sinus rhythm. The baseline ST segment should have ≤ 0.1 mV deviation, and the morphology ideally should be gently upsloping with an upright T wave. Although an ST segment that is flat or associated with an inverted T wave may still be interpretable, downsloping or scooped ST-segment morphology should be avoided. The R-wave height of the monitored lead should be ≥ 10 mm. Patients whose 12-lead ECG demonstrates left ventricular (LV) hypertrophy, preexcitation, left bundle-branch block, or nonspecific intraventricular conduction delay ≥ 0.10 second are not suitable for detecting ischemia by AECG. The lead selected for AECG ischemia monitoring should not have a Q wave ≥ 0.04 second or marked baseline ST-segment distortion. ST-segment deviation in the presence of right bundle-branch block may be interpretable, especially in the left precordial leads. Medications such as digoxin and some antidepressants distort the ST segment and preclude accurate interpretation of ST-segment deviation. ST-segment deviation is usually tracked by the use of cursors at the P-R segment to define the isoelectric reference point and at the J-point and/or 60 to 80 ms beyond the J-point to identify the presence of ST-segment deviation. Ischemia is diagnosed by a sequence of ECG changes that include flat or downsloping ST-segment depression ≥ 0.1 mV, with a gradual onset and offset that lasts for a minimum period of 1 minute. Each episode of transient ischemia must be separated by a minimum duration of at least 1 minute, during which the ST segment returns back to baseline ($1 \times 1 \times 1$ rule) (35), although many investigators prefer a duration of at least 5 minutes between episodes. We recommend a 5-minute interval between

episodes because the end of one episode and the onset of another episode will take longer than 1 minute to be physiologically distinct.

During superimposition scanning, the system displays the normal complexes used for ST-segment measurement. The magnitude of ST-segment deviation and the slope of the ST segment typically is identified and presented as part of a 24-hour trend. Episodes of ST-segment deviation are characterized by identification of an onset and offset time, magnitude of deviation, and heart rate before and during the episode. Representative ECG strips at the time of ST-segment deviation in real time may be provided in the report format. Ischemic episodes are displayed in a summary table. Miniaturized full-disclosure display can be printed for all or part of the 24-hour recording.

G. Emerging Technologies

There are a number of important new technologies that hold promise for the future. During the playback of the recorded ECG signal and the analysis process, there are electrophysiological variables that can be measured other than arrhythmias and ST-segment deviation. These include T-wave alternans (6), Q-T interval dispersion (36), and signal-averaged analysis (37). For these analyses, high-resolution data are necessary, which may require data acquisition at rates up to 1000 samples per second (38).

III. HEART RATE VARIABILITY

A. General Considerations

Analysis of R-R variability has been available for several years and is generally referred to as HRV. The balance between the cardiac sympathetic and vagal efferent activity is evidenced in the beat-to-beat changes of the cardiac cycle. Determination of this HRV is often performed to assess patients with cardiovascular disease. Several systems are commercially available to analyze spectral and temporal parameters of HRV.

Analysis of the beat-to-beat oscillation in the R-R interval is generally performed by 2 methods. Spectral analysis provides an assessment of the vagal modulation of the R-R interval. Spectral analysis is most commonly accomplished by fast Fourier transformation to separate R-R intervals into characteristic high (0.15 to 0.40 Hz), low (0.04 to 0.15 Hz), very low (0.0033 to 0.04 Hz), and ultra low (up to 0.0033 Hz) frequency bands. Spectral measures are collected over different time intervals (approximately 2.5 to 15 minutes), depending on the frequency being analyzed (39). Parasympathetic tone is primarily reflected in the high-frequency (HF) component of spectral analysis (40-42). The low-frequency (LF) component is influenced by both the sympathetic and parasympathetic nervous systems (43,44). The LF/HF ratio is considered a measure of sympathovagal balance and reflects sympathetic modulations (45).

Table 1. Components of HRV

Spectral Component	Time-Domain Correlates	Normal Measures for 24 Hours
HF	rMSSD	<15 h
	pNN50	<0.75%
LF	SDNN index	<30 ms
VLF	SDNN index	<30 ms
ULF	SDNN	<50 ms
	SDANN	<40 ms
	HRV index	...
TP	SDNN	<50 ms
	HRV index	...

VLF indicates very-low frequency; ULF, ultra-low frequency; TP, total power; SDNN index, mean of standard deviation of R-Rs; HRV index, integral of the total number of normal R-Rs divided by the maximum of the density distribution (an expression of overall 24-hour HRV).

From References 54, 56, and 57.

Nonspectral or time domain parameters involve computing indexes that are not directly related to specific cycle lengths. This method offers a simple means of defining patients with decreased variability in the mean and standard deviations of R-R intervals. Time domain parameters analyzed include mean R-R, the mean coupling interval between all normal beats; SDANN, standard deviation of the averaged normal sinus R-R intervals for all 5-minute segments of the entire recording; SDNN, standard deviation of all normal sinus R-R intervals; SDNN index, mean of the standard deviations of all normal R-R intervals for all 5-minute segments of the entire recording; pNN50, the percentage of adjacent R-R intervals that varied by more than 50 ms; and rMSSD, the root mean square of the difference between the coupling intervals of adjacent R-R intervals. Another time domain measure of HRV is the triangular index, a geometric measure obtained by dividing the total number of all R-R intervals by the height of the histogram of all R-R intervals measured on a discrete scale with bins of 7.8 ms. The height of the histogram equals the total number of intervals found in the modal bin. These 2 analytical techniques are complementary in that they are different mathematical analyses of the same phenomenon. Therefore certain time and frequency domain variables correlate strongly with each other (Table 1).

B. Technical Requirements for Recording and Analysis

1. Duration of Recording. Depending on the specific indication for analysis of HRV, either long-term (24-hour) or short-term (5-minute) recordings are made. HRV increases with increased periods of observation, and it is important to distinguish ranges on the basis of duration of recording. The Task Force of the European Society of Cardiology (ESC) and the North American Society of Pacing and Electrophysiology (NASPE) (45) provided frequency ranges for each parameter of HRV obtained during short- and long-term recordings (Table 2).

Frequency domain methods are preferable for short-term

Table 2. Selected Frequency Domain Measures of HRV

Variable	Units	Description	Frequency Range
Analysis of Short-Term Recordings (5 min)			
5-min total power	ms ²	The variance of NN intervals over the temporal segment	≈ ≤0.4 Hz
VLF	ms ²	Power in the VLF range	≤0.04 Hz
LF	ms ²	Power in the LF range	0.04-0.15 Hz
LF norm	nu	LF power in normalized units LF/(total power-VLF)×100	
HF	ms ²	Power in the HF range	0.15-0.4 Hz
HF norm	nu	HF power in normalized units HF/(total power-VLF)×100	
LF/HF		Ratio LF [ms ²]/HF [ms ²]	
Analysis of Entire 24 Hours			
Total power	ms ²	Variance of all NN intervals	≈ ≤0.4 Hz
ULF	ms ²	Power in the ULF range	≤0.003 Hz
VLF	ms ²	Power in the VLF range	0.003-0.04 Hz
LF	ms ²	Power in the LF range	0.04-0.15 Hz
HF	ms ²	Power in the HF range	0.15-0.4 Hz
α		Slope of the linear interpolation of the spectrum in a log-log scale	≈ ≤0.04 Hz

VLF indicates very-low frequency; ULF, ultra-low frequency.

Reprinted with permission from Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. *Circulation* 1996;93:1043-65.

recordings. Recording should last at least 10 times the duration of the wavelength of the lowest frequency under investigation. For example, recordings should be approximately 1 minute for short-term evaluation of the HF and 2 minutes for evaluation of LF. The authors of the ESC/NASPE Task Force recommend standardization at 5-minute recordings for short-term analysis of HRV (45), which is endorsed by this Task Force.

2. Artifact and Arrhythmias. No matter whether short- or long-term data are analyzed, the analysis of HRV depends on the integrity of the input data. Most systems obtain computer-digitized ECG signals. The R-R intervals are derived either on-line or off-line. The rate of digitization varies from system to system. Many commercial AECG systems have a digitization rate of 128 Hz, which is not optimal for some experimental short-term recordings but is useful for long-term recordings in adults (46).

To optimize the temporal accuracy of R-wave peak identification, especially when the digitization rate is below 250 Hz, a template matching or interpolation algorithm should be used (45,47,48). Similarly, artifact or noise in the ECG signal can create errors in R-wave timing. Several approaches to this problem have been taken and include smoothing or filtering the digitized data (47-49). Although these methods help to reduce inaccuracies created by recorded noise, careful patient preparation and maintenance of recording equipment is very important to eliminate noise before it occurs.

If analog recording devices are used, rates of digitization are not a factor, but noise and other errors in R-wave timing remain important. AECG systems that record on magnetic

tape for off-line processing can introduce errors related to tape stretch. The ESC/NASPE Task Force (45) provided guidelines for the routine evaluation of recording systems through simulated calibration signals with known characteristics.

A problem with ambulatory recordings for the determination of HRV is motion-related artifact. Missing R waves or spuriously detected beats can lead to large deviations in the R-R interval. Manual overview can usually detect these errors but can be tedious. Distribution-based artifact detection algorithms are best used to assist the visual approach (50-52).

An additional factor that introduces difficulties in the analysis of HRV is the presence of cardiac arrhythmias. HRV analysis is not possible with persistent atrial fibrillation. Intermittent abnormal heartbeats can distort the normal R-R intervals. Although HRV may be useful in predicting or characterizing abnormal rhythms, the presence of abnormal heartbeats must be processed in some way to avoid errors in the assessment of HRV. Two methods for handling abnormal heartbeats include interpolation of occasional abnormal beats (53) and limiting analysis to segments that are free of abnormal beats. Both methods have limitations, and application of both may be appropriate. However, in publications in which assumptions have been made, they must be stated clearly.

C. Day-to-Day Variability

In normal subjects, Kleiger et al (54) found 24-hour ambulatory recordings to reveal large circadian differences in the R-R interval, LF power, HF power, and LF/HF ratio.

Kleiger et al also described 3- to 4-fold changes in R-R variability between 5-minute segments of the same hour. However, the mean values for the LF and HF power were almost identical from day to day. Power spectral measures of R-R variability averaged across a 24-hour period were also essentially constant. Large differences were seen among the 5-minute intervals during the day (55). HRV in the normal population is affected by age and sex. Recent data have shown that SDNN index, rMSSD, and pNN50 in healthy people over the age of 60 years may actually fall below levels that have been associated with increased mortality rates. Younger women have less HRV than their age-matched counterparts, but these differences disappear by age 50 years. In subjects with coronary artery disease (CAD), Bigger et al (56) found no significant differences between 2 consecutive 24-hour recordings. Recommendations for the use of HRV analysis follow in Section V. K.

IV. ASSESSMENT OF SYMPTOMS THAT MAY BE RELATED TO DISTURBANCES OF HEART RHYTHM

A. Symptomatic Arrhythmias

One of the primary and most widely accepted uses of AECG is the determination of the relation of a patient's transient symptoms to cardiac arrhythmias (12,58,59). Some symptoms are commonly caused by transient arrhythmias: syncope, near syncope, dizziness, and palpitation. However, other transient symptoms are less commonly related to rhythm abnormalities: shortness of breath, chest discomfort, weakness, diaphoresis, or neurological symptoms such as a transient ischemic attack. Vertigo, which is usually not caused by an arrhythmia, must be distinguished from dizziness. More permanent symptoms such as those seen with a cerebrovascular accident can be associated less commonly with an arrhythmia, such as embolic events that occur with atrial fibrillation. A careful history is essential to determine if AECG is indicated.

If arrhythmias are thought to be causative in patients with transient symptoms, the crucial information needed is the recording of an ECG during the precise time that the symptom is occurring. With such a recording, one can determine if the symptom is related to an arrhythmia. Four outcomes are possible with AECG recordings. First, typical symptoms may occur with the simultaneous documentation of a cardiac arrhythmia capable of producing such symptoms. Such a finding is most useful and may help to direct therapy. Second, symptoms may occur while an AECG recording shows no arrhythmias. This finding is also useful because it demonstrates that the symptoms are not related to rhythm disturbances. Third, a patient may remain asymptomatic during cardiac arrhythmias documented on the recording. This finding has equivocal value. The arrhythmia may be useful as a clue to a more severe arrhythmia that actually causes symptoms. For example, nonsustained ventricular tachycardia recorded while the patient is asymptomatic may be a clue that the patient has a more serious

ventricular tachycardia at other times, causing near syncope or syncope. Likewise, asymptomatic bradycardia may be a clue that symptoms may occur when the heart rate is even slower. However, asymptomatic arrhythmias are common, even in the general population without heart disease (60-63). Therefore the recorded arrhythmia may or may not be relevant to the symptoms. Fourth, the patient may remain asymptomatic during the AECG recording, and no arrhythmias are documented. This finding is not useful.

It is imperative that the physician and patient be persistent in attempting to record the cardiac rhythm simultaneous with transient symptoms. This may require multiple 24- or 48-hour AECG recordings or event recorders (23,64-69), especially for infrequent symptoms. The rhythm must be recorded during and not after the symptoms have occurred. The utility of AECG will be determined by the frequency, severity, duration, and conditions under which the symptoms occur. Less frequent arrhythmias will require more attempts to record. Significant cardiac arrhythmias are more likely to occur in patients with serious heart disease, so it is more likely that transient symptoms can be correlated to arrhythmias in the severely ill cardiac patient. It is essential that a complete and detailed history and physical examination be taken, and it is often necessary to perform blood work, a chest radiograph, a 12-lead ECG, and/or an echocardiogram as a part of the initial evaluation. Careful clinical judgment must be exercised. Causes of symptoms other than arrhythmias must be considered and appropriate additional studies obtained. Under some circumstances, particularly in patients with exertional symptoms, an exercise test might give a higher yield for correlation between symptoms and cardiac rhythm. Electrophysiological studies and tilt-table testing also may be considered in certain circumstances. If symptoms are severe, monitoring may need to be performed in-hospital continuously on telemetry. However, the sensitivity and specificity of automatic rhythm monitoring alarms may be inferior to analysis of AECGs.

B. Selection of Recording Technique

The characteristics of the patient's symptoms will often determine the choice of recording techniques. Selection of technique must be individualized. Specific indications for the different types of recorders should not be defined here because such detail would place undue limits on clinical judgment. Continuous AECG recording may be particularly useful in patients who have complete loss of consciousness and would not be able to attach or activate an event recorder. Continuous AECG recording is particularly useful if symptoms occur daily or almost daily, although most patients do not have episodic symptoms this frequently. Such a recording should include a patient diary of symptoms and activities and the use of an event marker. The event marker is activated whenever the patient has typical symptoms, simplifying the identification of the point in time during the recording when symptoms occurred. Usually

Table 3. Yield of AECG Monitoring for Syncope*

Author (Reference)	No. of Patients	Symptoms at Presentation	Symptoms During Monitoring, n (%)		No Symptoms During Monitoring, n (%)	
			Arrhythmia	No Arrhythmia	Arrhythmia	No Arrhythmia
Bass et al (23)	95	Syncope	1 (1)	19 (20)	2 (26)	50 (53)
Kapoor et al (59)	249	Syncope	15 (6)	55 (22)	42 (17)	137 (55)
Gibson and Heitzman (66)	1512	Syncope, near syncope, dizziness	30 (2)	225 (15)	15 (10)	1101 (73)
Kala et al (67)	107	Syncope, dizziness	8 (7)	8 (7)	17 (16)	74 (69)
Zeldis et al (68)	74	Syncope, dizziness	10 (14)	18 (24)
Clark et al (69)	98	Syncope, dizziness	3 (3)	39 (39)	41 (41)	17 (17)
Boudoulas et al (78)	119	Syncope, dizziness	31 (26)	15 (13)	32 (27)	41 (34)
Jonas et al (79)	358	Syncope, dizziness	14 (4)	...	57 (16)	286 (80)
All studies†	2612		112 (4)	379 (15)	369 (14)	1706 (65)

*From Linzer et al (65), with permission.

†Totals do not add up to 100% because information was missing from 2 studies.

24-hour recordings are performed, although yield may be increased slightly with longer recordings or repeated recordings (23).

Many patients have symptoms occurring weekly or monthly, in which case a single continuous AECG recording probably will not be useful. An intermittent or event recorder (which is often capable of transtelephonic downloading) is more useful for infrequent symptoms (70-75).

Some rhythm recording devices are implanted surgically and include pacemakers, cardioverter-defibrillators, and newly developed ECG recorders (76,77). Their utility is limited by the need for an invasive procedure.

C. Specific Symptoms

Few studies have evaluated the sensitivity, specificity, positive and negative predictive values, and cost-effectiveness of the various recording techniques in patients with symptoms potentially related to cardiac arrhythmias. Only in the subset of patients with syncope are detailed data available.

1. Syncope. The diagnostic evaluation of syncope is determined by many clinical factors (59,64-67,69,76,78,79). Many studies combine evaluation of syncope with near syncope and/or dizziness (Table 3) and use different arrhythmia end points to define a "positive" study (66-69,78,79). Unfortunately, the yield of AECG monitoring is relatively low. The majority of such patients have no symptoms during ambulatory recording, and further evaluation is necessary. However, because of the severity of the symptoms, such testing is usually warranted. Nevertheless, the rhythm during asymptomatic periods may be useful. For example, a patient may have syncope only during severe bradycardia. An ambulatory ECG that shows intermittent episodes of asymptomatic bradycardia may suggest the diagnosis and prompt further evaluation. One study (23) evaluated the utility of repeated 24-hour ambulatory recording on 3 separate occasions. The first 24-hour recording exhibited a major abnormality in 15% of the patients. The

additive yield was 11% on the second and 4.2% on the third sequential recordings. Factors that identified a useful recording were advanced age, male sex, history of heart disease, and initial rhythm other than normal sinus. When continuous AECG monitoring is not useful, intermittent recorders (both patient-applied and loop) add incremental value to continuous recording. Furthermore, the memory capability of previously implanted pacemakers and ICDs can add diagnostic value.

Insufficient data exist regarding near syncope or dizziness alone to estimate the sensitivity and specificity of AECG recording for these conditions (12).

2. Palpitation. The yield of ambulatory monitoring that captures an episode of palpitation (Table 4) is higher than the yield for patients with syncope, probably because the frequency of occurrence of palpitation is higher than the occurrence of syncopal episodes, though findings are likely to be more variable in patients with palpitation (58,71). Palpitation accounts for 31% to 43% of indications for outpatient AECG monitoring (68,69). Furthermore, in patients with preexisting palpitation, asymptomatic episodes of supraventricular arrhythmias are more common than symptomatic episodes (80,81).

3. Other Symptoms. Other cardiac symptoms such as intermittent shortness of breath, unexplained chest pain, episodic fatigue, or diaphoresis might be related to cardiac arrhythmias. AECG monitoring may be indicated for these symptoms. Other conditions such as stroke or transient ischemic attack may be associated with cardiac arrhythmias, which could be detected by AECG (79,82).

Indications for AECG to Assess Symptoms Possibly Related to Rhythm Disturbances

Class I

- 1. Patients with unexplained syncope, near syncope, or episodic dizziness in whom the cause is not obvious**

Table 4. Yield of AECG Monitoring for Palpitation

Author (Reference)	No. of Patients	Symptoms at Presentation	Type of Monitoring	Symptoms During Monitoring, n (%)		No Symptoms During Monitoring, n (%)		Unknown [§]
				Arrhythmia	No Arrhythmia	Arrhythmia	No Arrhythmia	
Diamond et al (58)	85	Palpitation	24-h	37 (44)	17 (20)	3 (4)	28 (33)	142 (77)
Shimada et al (74)	184	Palpitation, chest pain, other	Event recorder	42 (23)	†	*	*	
Assayag et al (83)	1091	Palpitation (85%)	Event recorder	464 (43)	†	*	*	627 (57)
Kimlay et al (71)	43	Palpitation	48-h	0 (0)‡	15 (35)	§	§	28 (65)
			Event recorder	8 (19)‡	21 (49)	*	*	14 (33)

*Recording only performed during symptoms.
 †Not specified how many patients transmitted an ECG.
 ‡Clinically significant arrhythmia.
 §Not specified for asymptomatic patients.
 ||n = 29 transmissions.

2. Patients with unexplained recurrent palpitation

Class IIb

1. Patients with episodic shortness of breath, chest pain, or fatigue that is not otherwise explained
2. Patients with neurological events when transient atrial fibrillation or flutter is suspected
3. Patients with symptoms such as syncope, near syncope, episodic dizziness, or palpitation in whom a probable cause other than an arrhythmia has been identified but in whom symptoms persist despite treatment of this other cause

Class III

1. Patients with symptoms such as syncope, near syncope, episodic dizziness, or palpitation in whom other causes have been identified by history, physical examination, or laboratory tests
2. Patients with cerebrovascular accidents, without other evidence of arrhythmia

V. ASSESSMENT OF RISK IN PATIENTS WITHOUT SYMPTOMS OF ARRHYTHMIAS

AECG monitoring has been increasingly used to identify patients, both with and without symptoms, at risk for arrhythmias. The selection of patients for different types of devices and duration of recording is similar to that previously discussed in Sections II and III.

A. After Myocardial Infarction

Myocardial infarction (MI) survivors are at an increased risk of sudden death, with the incidence highest in the first year after infarction (84,85). The major causes of sudden death are ventricular tachycardia and ventricular fibrillation. The risk of developing an arrhythmic event has declined with the increasing use of thrombolytic agents and coronary revascularization (86-88). Currently, the 1-year risk of developing a malignant arrhythmia in an MI survivor after hospital discharge is 5% or less (86,87,89-91). The goal in risk-stratifying patients is to identify a population of patients at high risk of developing an arrhythmic event and reduce such events with an intervention. Ideally, these patients would be identified by a test or combination of tests with a high sensitivity and a very high positive predictive accuracy, so that as few patients as possible are unnecessarily exposed to treatment.

AECG monitoring usually is performed over a 24-hour period before hospital discharge. Some studies suggest that 4 hours of AECG monitoring provides as much information as 24 hours (92,93). In many studies, AECG monitoring was performed at least 6 and often approximately 10 days after the acute MI (Table 5). Frequent premature ventricular contractions (PVCs) (eg, 10 per hour) and high-grade ventricular ectopy (eg, repetitive PVCs, multi-form PVCs, ventricular tachycardia) after MI have been

Table 5. Sensitivity and Specificity of AECG for Predicting Arrhythmic Events After MI

Author (Reference)	No. of Patients	Criteria	Sensitivity, %	Specificity, %	PPV, %	NPV, %	End Points
Olson et al (174)	115	≥10 PVCs/h or multiform or pair or VT	25	79	12	90	Cardiac death
Kostis et al (96)	1640	≥10 PVCs	25	88	6	96	Sudden death
		≥10 PVCs/h or PVC pair or VT	43	75	8	96	
		≥10 PVCs/h or (PVC pair or VT) or multiform	67	61	8	97	
Mukharji et al (94)	533	≥10 PVCs/h and (PVC pair or VT) and multiform	16	94	11	96	Sudden death
de Cock et al (98)	99	≥10 PVCs/h	10	93	8	95	Death or MI
		≥10 PVCs/h	44	83	52	78	
		VT	26	100	100	75	
		SVT	41	97	86	80	
Farrell et al (89)	416	PVCs >10/h	54	82	16	82	Arrhythmic event
		Repetitive PVCs	54	81	15	97	
Richards et al (175)	358	Lown 3-5	82	40	6	98	Arrhythmic event
		Lown 3-5	75	76	16	98	Cardiac death
McClements and Adgey (86)	301	≥10 PVCs/h or repetitive	38	74	6	96	Arrhythmic event
Pedretti et al (100)	305	≥2 runs NSVT	42	91	25	96	Arrhythmic event
Hohnloser et al (87)	173	Lown 4	22	78	5	95	Arrhythmic event
El-Sherif et al (90)	1158	≥10 PVCs/h or VT	61	69	8	98	Arrhythmic event

NPV indicates negative predictive value; VT, ventricular tachycardia; SVT, supraventricular tachycardia; and NSVT, nonsustained ventricular tachycardia.

associated with a higher mortality rate among MI survivors (86,89-91,94-100). However, once patients have at least 6 PVCs per hour, the risk of an arrhythmic event does not increase with more frequent PVCs (101). The association between ventricular arrhythmias and adverse cardiac events has been demonstrated primarily in men (102,103).

The positive predictive value (PPV) of ventricular ectopy in most of these studies for an arrhythmic event has been low, ranging from 5% to 15%. The sensitivity of ventricular ectopy can be increased by combining it with decreased LV function. The PPV increases to 15% to 34% for an arrhythmic event if one combines AECG monitoring with an assessment of LV function (90,94,104,105).

Low values for high frequency measures of HRV (eg, rMSSD or pNN50) and baroreflex sensitivity (BRS) indicate decreased vagal modulation of R-R intervals (45,106). The specific mechanism by which HRV and BRS are reduced after MI remains unknown, but they decrease in patients early after MI (reaching a nadir after 2 to 3 weeks) and then increase back to normal levels by 6 to 12 months. Decreased HRV and BRS are independent predictors of increased mortality rates, including sudden death, in patients after MI (89,95,100,104,106-108) (Table 6). However, the predictive value of both HRV and BRS after MI, although statistically significant, is poor when used alone.

HRV may be determined from traditional 24-hour AECG monitoring or from shorter-duration monitoring. Although HRV measured from short-term recordings is depressed in patients at high risk, the predictive value increases with length of recording (109,110). Shorter-term recordings have lower specificity compared with 24-hour recordings in predicting patients at high risk, and there may be diurnal variation in HRV in some patients (110-112). The optimal time-domain parameters for analysis of risk are SDNN and HRV triangular index. High-risk patients have either an SDNN <70 ms, HRV triangular index <15, or BRS <3 ms/mm Hg. These patients may also be identified by examining power in the ultra-low-frequency range.

Although each of these tests has a predictive value independent of other well-established risk factors after MI, such as depressed LV function, their overall value is low. Combining these tests with each other and other clinical factors markedly improves their PPVs. As seen in Table 7, a variety of combinations has been used; however, it is not clear which is the best combination to use at the present time. The prognostic capability of these tests is reviewed in Table 8.

The combined use of AECG monitoring, LV function, and signal-averaged ECG has improved the positive predictive accuracy of risk stratification (sensitivity 80% and specificity 89%) (97). Also, Farrell et al (89) showed that reduced HRV and the presence of late potentials on signal-averaged ECG were a strong predictor of arrhythmic events after MI. These findings were present in only 10% of their patients, and even in this group the PPV was limited to 33%. The ATRAMI (Autonomic Tone and Reflexes

Table 6. Sensitivity and Specificity of HRV for Predicting Arrhythmic Events After MI

Author (Reference)	No. of Patients	Criteria	Sensitivity, %	Specificity, %	PPV, %	NPV, %	End Points
Kleiger et al (95)	808	HRV <50 ms*	34	88	34	88	All-cause death
Farrell et al (89)	416	HRV triangular index <20†	92	77	17	77	Arrhythmic event
		Mean R-R interval <750 ms	67	72	13	97	
Odemyiwa et al (107)	385	HRV triangular index ≤30†	75	76			Arrhythmic event
Bigger et al (104)	715	ULF	28	93	41		All-cause death
		VLF	30	92	39		
		ULF+VLF	20	96	48		
Pedretti et al (100)	294	HRV triangular index ≤29†	89	68	15	99	Arrhythmic event
La Rovere et al (106)	1170	HRV <70 ms*	39	85	10	97	Arrhythmic event† and cardiac death
		BRS <3.0 ms/mm Hg	35	86	10	97	Arrhythmic event‡ and cardiac death

NPV indicates negative predictive value; ULF, ultra-low-frequency power; and VLF, very-low-frequency power.

*HRV calculated using SDNN (standard deviation of all NN intervals).

†Total number of all NN intervals divided by the height of the histogram of all NN intervals measured on a discrete scale with bins of 7.8125 ms (1/128 seconds).

‡Arrhythmic event defined as nonfatal cardiac arrest caused by documented ventricular fibrillation.

after Myocardial Infarction) study also examined the practice of combining multiple markers of HRV. It showed that the presence of both a reduced HRV and reduced BRS increased a patient's relative risk of cardiac events 7-fold, but these 2 findings were present in only 5% of the patients (106). Adding more clinical findings (eg, ejection fraction) and demographic features (eg, age) further improves the ability to identify high-risk subgroups, but these patients represent very small proportions of the population (106). AECG is not needed in asymptomatic post-MI patients who have an ejection fraction of ≥40% (100) because malignant arrhythmias occur infrequently in such patients.

Long-term survivors of MI with reduced LV function remain at increased risk of dying from a cardiovascular event. However, the primary reason for patients to undergo AECG monitoring is to identify those with a poorer prognosis and ultimately to improve outcomes through active treatment. Recently, the Multicenter Automatic Defibrillator Implantation Trial (MADIT) showed that ICD therapy reduces mortality rates by approximately 50% in MI survivors who had a reduced LV ejection fraction (≤35%), who had at least 1 asymptomatic nonsustained ventricular arrhythmia, and in whom ventricular fibrillation or sustained ventricular tachycardia was reproducibly induced during electrophysiological testing and not suppressed by use of intravenous procainamide (113). Unfortunately, the study does not provide data on how many patients after MI had this combination of findings nor how many were identified as having asymptomatic ventricular arrhythmias detected only by AECG.

Similarly, a recent meta-analysis examined whether amiodarone prevented sudden death in a series of randomized controlled trials (114). Amiodarone reduced the incidence of sudden death, cardiac death, and total mortality rates in these trials. However, the patient populations were heterogeneous, and only two thirds of the trials required ventric-

ular ectopy for study entry. In addition, survival for patients who received amiodarone was only different from the usual and active care groups; there was no significant difference when compared with placebo (ie, the alternative treatment may have been harmful, and this could have artificially increased the effect of amiodarone). Thus the role of AECG in identifying this population remains unanswered.

B. Congestive Heart Failure

Patients with congestive heart failure (CHF), whether caused by an ischemic cardiomyopathy or an idiopathic dilated cardiomyopathy, often have complex ventricular ectopy and a high mortality rate (115,116). There were conflicting findings in a series of small studies, with some suggesting a relation between ventricular arrhythmias and death (117-119) and others finding no such relation (115,116,120). Several more recent studies with larger populations have found that ventricular arrhythmias (eg, ventricular tachycardia, nonsustained ventricular tachycardia) are sensitive but not specific markers of death (121,122) and sudden death (122) (Table 9). Despite identifying a population with an increased relative risk of an adverse event, these tests are either not sensitive or have low PPVs.

HRV is decreased in patients with CHF (123,124). This decrease is improved with the use of angiotensin-converting enzyme inhibitor treatment (125,126). However, there are divergent results with respect to the association between HRV and arrhythmic events (127-132). In addition, there is no evidence that reducing the frequency of these arrhythmias or increasing the HRV with medications can significantly reduce the incidence of total death or sudden death in patients with severe CHF (114). Thus there is not sufficient evidence to support the routine use of AECG or HRV in patients with CHF or dilated cardiomyopathies.

Table 7. Sensitivity and Specificity of Combining Noninvasive Tests for Predicting Arrhythmic Events After MI

Author (Reference)	No. of Patients	Criteria	Sensitivity, %	Specificity, %	PPV, %	NPV, %	End Point
Olson et al (174)	115	EF <40%+(>10 PVCs/h or multiform or pairs of VT)	50	91	40	94	Cardiac death
Kuchar et al (97)	206	Lown grade 3 to 5+(RMS <20 μ V or QRS >120 ms)	65	89	34	97	Arrhythmic event
Mukharji et al (94)	533	EF <40%+(RMS <20 μ V or QRS >120 ms)	80	89	60	98	
Farrell et al (89)	416	EF <40%+(>10 PVCs/h)	24	93	18	96	Sudden death
		HRV <20 ms+late potential (A)	58	93	33	93	Arrhythmic event
		HRV <20 ms+>10 PVCs/h	50	94	34	96	
		HRV <20 ms+repetitive PVC	50	96	43	77	
		HRV <20 ms+repetitive PVC+late potential (A)	29	99	58	95	
		EF <40%+late potential (A)	25	94	19	94	
		EF \leq 40%+>10 PVCs/h	33	93	19	94	
		EF \leq 40%+repetitive PVC	25	91	15	95	
		EF <40%+>10 PVCs/h+late potential (A)	20	97	28	97	
Bigger et al (104)	715	EF \geq 40%+ \geq 3 PVCs/h	32	89	34		Total death
		\geq 3 PVCs/h+ULF+VLF	8	98	53		
		EF <40%+ULF+VLF	14	98	56		
		EF <40%+ \geq 3 PVCs/h+ULF+VLF	6	99	50		
Zhang et al (105)	60	[QRS \geq 120 ms or (RMS <25 μ V+LAS >40 ms @ 40 Hz)]	100	97	33	100	Arrhythmic event
		+(>10 PVCs/h or couplets or NSVT or VT)					
		[QRS \geq 120 ms or (RMS <25 μ V+LAS >40 ms @ 40 Hz)]	80	72	29	96	
		+EF <45%					
		EF <45%+(\geq 10 PVCs/h or couplets or NSVT or VT)	57	73	26	91	
		[QRS \geq 120 ms or (RMS <25 μ V+LAS >40 ms @ 40 Hz)]	100	93	60	100	
		+EF <45%+(\geq 10 PVCs/h or couplets or NSVT or VT)					
McClements and Adegoy (86)	301	EF <40% or (RMS <25 μ V+LAS >40 ms @ 25 Hz)	85	67			Arrhythmic event
Pedretti et al (100)	292	\geq 2 of the following: EF \leq 40%+late potential (B)+Lown 4	89	82	24	99	Arrhythmic event
		\geq 2 of the following: EF \leq 40%+HRV <29+QRSD >106 ms	83	83	25	99	
		\geq 2 of the following: EF \leq 40%+ \geq 2 runs NSVT+QRSD >106 ms	89	93	44	99	
Hohnloser et al (128)	173	Ocluded IRA	89	82	22	99	Arrhythmic event
		Ocluded IRA+EF \leq 40%	83	91	31	99	
		Ocluded IRA+late potential (B)	83	90	31	99	
		Ocluded IRA+EF \leq 40%+late potential (B)	75	97	50	99	
El-Sherif et al (90)	1158	EF <40%+(\geq 10 PVCs/h or VT)	58	86	15	98	Arrhythmic event
		EF <40%+QRS \geq 120 ms+(\geq 10 PVCs/h or VT)	33	97	32	97	
		QRS \geq 120 ms+(\geq 10 PVCs/h or VT)	36	95	24	97	
		EF <40%+QRS \geq 120 ms	39	95	25	97	

NPV indicates negative predictive value; OR, odds ratio; VT, ventricular tachycardia; EF, ejection fraction; LAS, low-amplitude signal; IRA, infarct-related artery; ULF, ultra-low-frequency power; VLF, very-low-frequency power. Late potential (A), present if any 2 of the following criteria were present: QRS >120 ms, RMS voltage of last 40 ms of QRS complex <25 μ V, LAS >40 ms after voltage decreased to <40 μ V. Late potential (B), present if any 2 of the following criteria were present: QRS >114 ms, RMS voltage of last 40 ms of QRS complex <20 μ V, LAS >38 ms after voltage decreased to <40 μ V. RMS, root mean square voltage of the last 40 ms of the QRS complex; LAS duration of the low-amplitude signal (<40 μ V) in the terminal portion of the QRS complex.

Table 8. Determining Prognosis of Acute MI Survivors Who Underwent 24-Hour AECG Monitoring

Author (Reference)	No. of Patients	Time Between AMI and AECG	Mean Follow-Up Duration	Tested Variables	Significant Variables	RR, Total Death	RR, Cardiac Death	RR, Arrhythmic Event
Mukharji et al (94)	533	10 d	18 mo	12 Clinical 1 Nuc Med 3 Holter	≥10 PVCs/h EF ≤40%		S	
Kleiger et al (95)	808	11 d	31 mo	2 Clinical 2 AEM 1 Nuc Med	Rales EF <30% PVCs ≥10/h HRV <50	2.4 2.0 1.9 1.7		
Kostis et al (96)	1640	2-21 d	25 mo	11-15 Clinical 11 Holter	NYHA class III/IV ≥10 PVCs/h Multiform PVC ≥10 PVCs/h or PVC pair or VT ≥10 PVCs/h or (PVC pair or VT) or multiform	2.2* 1.7 2.1 2.0	2.4 1.7 2.2	
Kuchar et al (97)	206	11 d	14 mo	1 Holter 1 SAECG 1 Nuc Med	RMS <20 μV or QRS ≥120 ms EF <40% Lown 3-5			23.6* 17.9 7.6
Gomes et al (91)	94	10 d	14 mo	9 Clinical 7 Holter 9 SAECG	QRS >114 ms @ 40 Hz PVC pairs EF (continuous variable)	S S S		
de Cock et al (98)	99	14 d	56 mo	2 Nuc Med 11 Clinical 13 AEM	SVT VT 10 PVCs/h		S S S	
Farrell et al (89)	416	6-7 d	≈20 mo†	6 Clinical 5 AEM	Killip class ≥II HRV triangular index <20 ms Late potential (A) Repetitive PVCs	S		S S S
Richards et al (175)	358	7-10 d	≈24 mo†	5 Clinical 1 Nuc Med 1 EST 1 EPS 2 AEM	Killip class ≥II EF ≤40% QRS ≥120 ms			3.1 4.5
Bigger et al (104)	715	11 d	30 mo	6 HRV 3 Clinical 1 Nuc Med 1 Holter	ULF VLF LF HF TP LF/HF	2.3 2.1 ... 1.7 2.1 1.7	2.3 2.2 1.9 1.8	2.3 2.5 1.9 1.8

Table 8. (continued).

Author (Reference)	No. of Patients	Time Between AMI and AECG	Mean Follow-Up Duration	Tested Variables	Significant Variables	RR, Total Death	RR, Cardiac Death	RR, Arrhythmic Event
Wilson and Kostis (99)	3290	2-21 d	25 mo	15 Clinical 1 AEM	≥1 PVC/h	S		
Bigger et al (112)	331	1 y	26 mo	3 Clinical 1 Nuc Med 3 Holter 6 HRV	VLF LF	4.4 3.8		
McClements and Adgey (86)	301	2-6 d	12 mo	20 Clinical 12 AEM	≥10 PVCs/h or PVC pair (QRS >120 ms or RMS <25 μV + LAS >40 ms @ 25 Hz)			S S
Pedretti et al (100)	305	24-48 d	15 mo	6 Clinical 7 AEM	EF <40% HRV triangular index ≤29 QRSD ≥106 ≥2 runs NSVT			16 15 9 6
Hohnloser et al (128)	173	Before discharge	12 mo	11 Clinical 2 Nuc Med 2 Cath 1 SAECC	Patent infarct-related artery			S
El-Sherif et al (90)	1158	5-30 d	10 mo	10 Clinical 2 Holter 6 SAECC	EF <40% + (≥10 PVCs/h or VT) EF <40% + (≥10 PVCs/h or VT) + QRS ≥120 ms (≥10 PVCs/h or VT) + QR ≥120 ms EF <40% + QRS ≥120 ms			8.4 16.7 11.0 12.2
Olona et al (176)	115	7-15 d	≥5 y	5 EST 5 Thallium 3 Echo 6 Nuc Med 2 Holter 4 Cath	None			

AMI indicates acute MI; RR, relative risk; Nuc Med, nuclear medicine; EF, ejection fraction; AEM, ambulatory electrocardiographic monitoring; NYHA, New York Heart Association; VT, ventricular tachycardia; RMS, root mean square; SAECC, signal-averaged ECG; SVT, supraventricular tachycardia; EST, ECG stress test; EPS, electrophysiologic study; ULF, ultra-low frequency power; VLF, very-low-frequency power between 0.003 and 0.04 Hz; TP, total power; LAS, low-amplitude signal; NSVT, nonsustained ventricular tachycardia; Cath, catheterization; and Echo, echocardiogram.
*Odds ratio instead of relative risk ratio; S, significant finding, no relative risk calculated.
†Median follow-up duration.

Table 9. Sensitivity and Specificity of AECG and HRV for Predicting Arrhythmic Events in Patients With CHF

Author (Reference)	No. of Patients	Criteria	Sensitivity, %	Specificity, %	PPV, %	NPV, %	Adjusted RR (95% CI)	End Points
Doval et al (122)	516	NSVT	58	70	24	91	2.6 (1.6-4.1)	Sudden death
	295	NSVT or couplets	89	42	21	96	2.9 (1.1-7.6)	Sudden death
	516	NSVT	45	73	50	69	1.6 (1.2-2.2)	Total death
	295	NSVT or couplet	76	32	51	74	10.1 (1.9-52.7)	Total death
Szabo et al (121)*	204	VT	60	72	38	86		Cardiac death
Pelliccia et al (119)	104	Lown class ≥ 4	31	88	58	72		Cardiac death
Ponikowski et al (130)	102	SDNN < 100	79	67	37	93		Total death
Huang et al (115)	35	NSVT	50	65	5	93		Sudden death
Igekawa (120)*	33	NSVT	71	81	50	91		Sudden death
		≥ 100 PVCs/h	71	81	45	91		
		NSVT + ≥ 100 PVCs/h	57	96	80	89		
Holmes et al (117)	31	Lown class ≥ 4	7	53	11	41		Cardiac death

NPV indicates negative predictive value; NSVT, nonsustained ventricular tachycardia; VT, ventricular tachycardia.

*Calculations are derived from figures in published articles.

C. Hypertrophic Cardiomyopathy

Sudden death and syncope are common among patients with hypertrophic cardiomyopathy. The exact relation between ventricular arrhythmias or HRV and outcomes for patients with hypertrophic cardiomyopathy remains open to question. Three studies show that there is some association between ventricular arrhythmias and adverse events, but they differ on the nature of the association (133-135). Another study found no association between HRV indexes and adverse events (136). Although AECG monitoring may add to the prognostic information provided by known risk factors for patients with hypertrophic cardiomyopathy, treatment of these ventricular arrhythmias has not consistently been shown to increase life expectancy. Hence the specific role of AECG in the day-to-day treatment of these patients remains unclear.

D. Valvular Heart Disease

A few studies have examined the relation between valvular heart disease and HRV or ventricular ectopy. At the present time, the presence of mitral valve prolapse (137), chronic mitral regurgitation (138), or aortic valve prosthesis (139) without other symptoms does not establish the need for AECG monitoring nor for assessing HRV.

E. Diabetic Neuropathy

Diabetes is associated with diffuse degeneration of sympathetic and parasympathetic small nerve fibers. More than half the patients with symptomatic diabetic neuropathy will die within 5 years (140). Because heart rate and rhythm are under the control of the autonomic nervous system, several groups have studied the relation between HRV and diabetic neuropathy. High-frequency measures of HRV can detect small changes in cardiac autonomic function in diabetic subjects (141-143) and can distinguish diabetic subjects with neuropathy from those without neuropathy (144). Although these tests are reliable and sensitive for cardiac

parasympathetic function, their clinical utility is limited for 2 reasons. First, large numbers of diabetic subjects have reduced HRV (142). Second, there is no evidence that early identification of subclinical diabetic neuropathy will lead to improved patient outcomes. In a report on the natural history of diabetic neuropathy, more than half the deaths were due to kidney failure and not cardiac arrhythmias (140). Thus, routine HRV testing is not indicated at this time.

F. Hemodialysis Patients

Patients with kidney failure who are receiving hemodialysis are at increased risk of dying from a cardiovascular event and have an increase in ventricular ectopy during dialysis (145). In a minority of these patients, significant ventricular arrhythmias develop (146). Those most at risk of having an abnormal AECG recording are patients with known coronary artery or peripheral vascular disease (147). Patients with Lown grade 3 or higher arrhythmia (148) have decreased survival compared with patients without ventricular ectopy (147). Whether this prognostic information justifies performing AECG monitoring on these patients is unknown.

G. Systemic Hypertension

Systemic hypertension is the most common cause of LV hypertrophy (149). Hypertensive patients with either ECG (150) or echocardiographic (151-153) criteria of LV hypertrophy have an increased incidence of complex ventricular arrhythmias. There is an increased risk of ventricular arrhythmias, MI, and sudden death in patients with LV hypertrophy (154,155). AECG monitoring of asymptomatic patients with LV hypertrophy is of uncertain value because those patients with complex or frequent arrhythmias have only a marginally significant risk of dying after adjusting for age, sex, and other clinical factors (OR 1.62; 95% CI 0.98-2.68) (156).

H. Preoperative and Postoperative Patients

AECG monitoring has been used in the preoperative evaluation of patients and after a variety of cardiac operations. No association has been found between preoperative ventricular arrhythmias and postoperative events when used before surgery in high-risk patients undergoing noncardiac surgery who have no myocardial ischemia and are without severe LV dysfunction (157). Similarly, no association has been found between the occurrence of complex ventricular ectopy after coronary artery bypass surgery and death after controlling for other clinical factors (158). Finally, although AECG is occasionally recommended for preoperative testing in patients with bundle-branch block, there are no data supporting this use.

I. Screening in Other Patients

There are conflicting results concerning the relation between asymptomatic ventricular arrhythmias and outcomes in the elderly, patients with obstructive lung disease, and others. Some studies demonstrate an increased risk and other studies show no difference in risk (159-164). AECG monitoring was not of value in patients who had sustained a myocardial contusion (165) nor in those with sleep apnea (166,167). Therefore there is insufficient evidence to support routine use of AECG monitoring in these patient populations.

J. Monitoring Pharmacological Management

Several medications used in the treatment of patients with cardiac conditions affect either directly or indirectly the autonomic nervous system. Analysis of R-R variability may provide a tool for understanding these various pharmacological manipulations (168-173). To date, the prognostic implications of the noted alterations are unknown. In drug development, analysis of R-R variability may provide insights into mechanisms of action. Future studies should include outcomes research.

K. Summary

Although arrhythmia detection and HRV analyses each provide some incremental information that may be useful in identifying patients without symptoms of arrhythmias at increased risk of future cardiac events, their overall value is limited at the present time because of their relatively low sensitivity and PPV. Combining AECG, HRV, signal-averaged ECG, and LV function improves the quality of the information provided, but the best way to combine data from these different tests remains elusive. Three groups may benefit from either AECG or HRV monitoring: patients with idiopathic hypertrophic cardiomyopathy, patients with CHF, and post-MI survivors with reduced ejection fraction. However, these tests cannot be recommended for routine use in any other population at the present time.

Indications for AECG Arrhythmia Detection to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia

Class I

None

Class IIb

1. Post-MI patients with LV dysfunction
2. Patients with CHF
3. Patients with idiopathic hypertrophic cardiomyopathy

Class III

1. Patients who have sustained myocardial contusion
2. Systemic hypertensive patients with LV hypertrophy
3. Post-MI patients with normal LV function
4. Preoperative arrhythmia evaluation of patients for noncardiac surgery
5. Patients with sleep apnea
6. Patients with valvular heart disease

Indications for Measurement of HRV to Assess Risk for Future Cardiac Events in Patients Without Symptoms From Arrhythmia

Class I

None

Class IIb

1. Post-MI patients with LV dysfunction
2. Patients with CHF
3. Patients with idiopathic hypertrophic cardiomyopathy

Class III

1. Post-MI patients with normal LV function
2. Diabetic subjects to evaluate for diabetic neuropathy
3. Patients with rhythm disturbances that preclude HRV analysis (ie, atrial fibrillation)

VI. EFFICACY OF ANTIARRHYTHMIC THERAPY

AECG has been widely used to assess the effects of antiarrhythmic therapy. The technique is noninvasive, provides quantitative data, and permits correlation of symptoms with ECG phenomena. However, limitations of AECG as a therapeutic guide affect its usefulness. These limitations include significant day-to-day variability in the frequency and type of arrhythmias in many patients, a lack of correlation between arrhythmia suppression after an intervention and subsequent outcome, uncertain guidelines for the degree of suppression required to demonstrate an effect, either statistical or clinical, and an absence of quantifiable spontaneous asymptomatic arrhythmias between episodes in many patients with a documented history of life-threatening arrhythmias (12).

The basis for the use of AECG has been the hypothesis that a reduction from baseline levels in arrhythmia frequency or type during serial monitoring after institution of therapy will correlate with an improved long-term clinical response. The majority of placebo-controlled, randomized data concerning this hypothesis has been generated in patients with asymptomatic ventricular ectopy. Uncontrolled data and data comparing AECG with electrophysiological studies are available in patients with prior sustained ventricular tachycardia or ventricular fibrillation. Because of the limited day-to-day occurrence of supraventricular arrhythmias and the uncertain significance of asymptomatic nonsustained atrial ectopy, quantitative analysis of long-term AECG recordings has not been widely used to guide therapy of supraventricular arrhythmias. However, intermittent monitoring to confirm the presence of an arrhythmia during symptoms and to document arrhythmia-free intervals has become a standard approach for evaluating the effects of antiarrhythmic therapy in patients with supraventricular arrhythmias (177). The AECG also may be used to monitor the effects of atrioventricular (AV) nodal blocking drugs on heart rate in patients with atrial arrhythmias.

A number of authors have examined the day-to-day variability in the frequency and type of arrhythmia detected in various patient populations (13–20,178–180). As shown in Table 10, short-term reproducibility of data between recordings was poor, and large reductions (63% to 95%) in arrhythmia frequency would be required to ensure that the change was due to an antiarrhythmic effect of any intervention. Long-term reproducibility of ventricular arrhythmia frequency and types is limited as well (17,21,181–184).

The Cardiac Arrhythmia Suppression Trial (CAST) tested the hypothesis that suppression of spontaneous ectopy by an antiarrhythmic drug would reduce mortality rates in patients with asymptomatic ventricular arrhythmias after MI (185–189). The active drugs used in the study were encainide, flecainide, and moricizine. In the initial design, all patients were assigned to active drug treatment, and suppression of spontaneous ectopy during a titration phase was monitored. Patients who did not manifest suppression were not randomly assigned and had a more than 2-fold higher mortality rate than did the patients whose arrhythmias were suppressed and who were randomly assigned to placebo (180,185–188). A higher mortality rate during follow-up was observed in those patients who had suppression and then received chronic encainide or flecainide therapy as opposed to placebo. After this observation, the trial design was altered and the study continued with moricizine as the only active agent. A higher mortality rate during a placebo-controlled drug titration with moricizine was observed, and there was no indication of benefit with long-term therapy (187).

The data from CAST led to a revision of many concepts concerning methods for guiding antiarrhythmic drug therapy in asymptomatic patients. It was seen that suppression of spontaneous asymptomatic or mildly symptomatic ven-

tricular ectopy with an antiarrhythmic drug might not only be ineffective but actually harmful. Thus therapy in such patients with Class I antiarrhythmic drugs is currently not recommended. The data also gave rise to the concept of the “healthy responder” (ie, patients who respond to an intervention, in this case AECG-guided drug therapy, may have a different prognosis than those who do not) (190). This observation influences the interpretation of data from other studies that do not include an untreated control group.

Controlled data from mortality trials with AECG as a guide to therapy with other antiarrhythmic agents are not available, but many trials have evaluated the unguided use of Class Ia, Class Ib, and selected Class III antiarrhythmic agents (191,192). These trials have demonstrated either no benefit or an adverse effect with antiarrhythmic drug therapy. Studies with empiric use of amiodarone have been inconsistent, with some studies showing a benefit (193–196) and others showing no significant change in mortality rates (88,197,198). In one trial (198), amiodarone produced a significant reduction in arrhythmia frequency but had no effect on mortality rate. It has not been demonstrated that amiodarone therapy guided by responses during serial AECG would improve these results.

Placebo-controlled trials of antiarrhythmic interventions in patients with sustained life-threatening ventricular arrhythmias are problematic. One favorable early report showed improvements in arrhythmia-free survival in patients who met certain criteria for a drug response during serial AECG (199,200). It is not possible to estimate the effects of the “healthy responder” phenomenon on these observations.

AECG has been compared with serial electrophysiological studies in 2 randomized trials in patients with prior sustained ventricular arrhythmias. A small study by Mitchell et al (201) suggested that an electrophysiological study-based approach was superior, whereas the much larger Electrophysiologic Study Versus Electrocardiographic Monitoring (ESVEM) study showed no difference in outcome with the use of the 2 approaches to select initial therapy (202). Both of these studies, however, had many important limitations, and firm conclusions about the relative value of the 2 approaches remain uncertain. Of note, the ESVEM trial did not include amiodarone, the agent most commonly selected in patients with serious arrhythmias in several recently completed antiarrhythmic trials (113,203).

It is also important to note that not all patients with a history of sustained ventricular tachycardia will manifest high-frequency or complex ventricular ectopy. Swerdlow and Peterson (204) found, in a cohort of patients with CAD and sustained ventricular arrhythmias, that 76% had spontaneous ventricular arrhythmias suitable for drug assessment on a 24-hour AECG. In the 2 randomized trials mentioned above that compared serial AECG versus electrophysiological testing for selecting drug therapy, Mitchell et al (201) and the ESVEM group (202) found that 32% and 17%, respectively, of patients approached had insufficient sponta-

neous ectopy to enter the trial. The former single-center trial study screened consecutive patients at that site who presented with a symptomatic ventricular arrhythmia and required ≥ 30 PVCs per hour for enrollment. ESVEM, a multicenter study performed at 14 sites, did not always obtain an AECG to quantify ventricular ectopy in patients with consecutive ventricular arrhythmia at the sites and required in the monitored patients only 10 PVCs per hour for enrollment.

It should be noted that the ICD offers an alternate strategy for treatment of patients with life-threatening ventricular arrhythmias. Many current-generation ICDs store event electrograms for retrieval, and ambulatory monitoring is now rarely required to assess ICD utility.

Very few patients with sustained supraventricular arrhythmias have episodes on a daily basis. Guidelines for assessing therapy for supraventricular arrhythmias based on a quantitative analysis of the frequency or pattern of asymptomatic atrial ectopic beats are not available. However, protocols for rigorous assessment of antiarrhythmic drug efficacy with intermittent monitoring have been developed and validated. In these protocols, patients are asked to record and transmit ECG data from intermittent recording monitors to document the presence of arrhythmias during symptoms (205). Once a baseline frequency has been established, therapy is begun and the "arrhythmia-free" interval is used as a measure of drug effect. This type of protocol is now accepted as the standard for an antiarrhythmic drug development program for supraventricular arrhythmias because it provides a statistically valid measure of drug effect on symptomatic arrhythmias in a given population (205,206). Asymptomatic arrhythmias, also commonly present, would not be detected unless long-term recordings or periodic surveillance transmissions were also obtained (80). Use of a similar protocol in routine practice is not common, but the use of intermittent recordings in a nonquantitative manner may be clinically useful in patients with recurrent symptoms. AECG recordings are also of value for documenting control of the ventricular rate in patients with continuous atrial arrhythmias because they provide data on the heart rate during the patient's typical daily activities.

The concept of proarrhythmia includes both provocation of new arrhythmia and exacerbation of preexisting arrhythmia as a result of antiarrhythmic drug therapy (207,208). Proarrhythmia may occur early or late during the course of therapy. In previously asymptomatic patients with ventricular ectopy, proarrhythmia is usually defined as an increase in frequency of ventricular premature depolarizations or of runs of ventricular tachycardia. The increase needed to differentiate proarrhythmia from day-to-day variability may be estimated statistically on the basis of baseline arrhythmia frequency (207,208). In CAST, patients who manifest an early increase in ventricular premature depolarization had a higher mortality rate when treated with placebo than did those without this finding (209). Increased QT intervals,

sinus node dysfunction, and new or worsened AV conduction abnormalities are other types of asymptomatic but still clinically relevant proarrhythmia that may be detected by AECG in patients receiving antiarrhythmic drug therapy.

Indications for AECG to Assess Antiarrhythmic Therapy

Class I

1. To assess antiarrhythmic drug response in individuals in whom baseline frequency of arrhythmia has been well characterized as reproducible and of sufficient frequency to permit analysis

Class IIa

1. To detect proarrhythmic responses to antiarrhythmic therapy in high-risk patients

Class IIb

1. To assess rate control during atrial fibrillation
2. To document recurrent symptomatic or asymptomatic nonsustained arrhythmias during therapy in the outpatient setting

Class III

None

VII. ASSESSMENT OF PACEMAKER AND ICD FUNCTION

Over the last 10 years, the function and diagnostic capabilities of pacemakers and ICDs have become more complex (210-215). As a result, trouble-shooting device function and determining optimal device programming has become more challenging. AECG is useful in correlating frequent symptoms with cardiac rhythm abnormalities and thereby can aid in evaluating symptomatic patients for pacemaker implantation. Guidelines have been previously set forth describing appropriate indications for permanent pacemaker implantation (216), and AECG is useful in both documenting the presence of significant bradyarrhythmias and establishing whether or not an association exists between a patient's symptoms and the presence of cardiac arrhythmia.

Once a device is implanted, AECG is useful in assessing postoperative device function as well as in guiding appropriate programming of enhanced features such as rate responsivity and automatic mode switching. AECG can sometimes be a useful adjunct to continuous telemetric observation after pacemaker implantation in assessing device function and thereby aid in determining the need for either device reprogramming or operative intervention (217). Present-generation pacemakers are capable of limited AECG monitoring function, which at the present time is not capable of entirely supplanting conventional AECG. They accomplish this with various algorithms by which complexes are classified according to whether or not they are preceded by atrial sensed or paced events (218). Tabular data can then be obtained from pacemaker memory at the time of follow-up interrogation, which quantifies how many

or what percentage of atrial and ventricular events were either sensed or paced, including a separate quantification of sensed ventricular events without preceding atrial activity. Although these algorithms were primarily designed to profile pacemaker activity to optimize device programming including AV delay, rate responsiveness, and upper and lower rate limits, these data can be used to broadly determine the frequency of ventricular ectopy. The resolution of the data, however, usually does not allow for minute-to-minute counts or detailed characterization of repetitive ectopy (ie, rate, duration, or morphology of ventricular tachycardia). Because present devices do not provide electrogram confirmation of these counts, the accuracy of the tabulated data provided by these devices depends on accurate sensing and pacing function. Undersensing or oversensing of cardiac events or events occurring during blanking or refractory periods will result in inaccurate counts.

When compared with pacemakers, present-generation ICDs are capable of more detailed electrogram recording of events precipitating device activation. These recordings, however, are made over a significantly more limited time duration (usually on the order of 5 to 30 seconds per event, up to approximately 5 to 10 minutes of total recording duration). Although these recordings provide more complete disclosure and allow for direct physician review, the limited recording duration and absence of a surface ECG with which to provide data regarding QRS morphology are substantial limitations. Currently under development are devices capable of AECG while acquiring on-line telemetric data from an implanted device (219). This data link can then be used to correlate device function with a recorded ECG signal, thus allowing for more detailed analysis of pacemaker or ICD function during a more prolonged time period.

During outpatient follow-up of patients undergoing device implantation, AECG is useful in correlating intermittent symptoms with device activity (76,220). Pacing thresholds in the atrium and ventricle evolve after lead implantation, and abnormalities of sensing and capture can be documented during chronic follow-up. Device longevity can be maximized with appropriate programming of output parameters, and AECG can be useful in assessing device function after such reprogramming.

Patients having undergone ICD implantation for the management of ventricular arrhythmias often have ICD shock therapy during follow-up. AECG can be a useful adjunct in establishing the appropriateness of such therapy (221,222). The efficacy of adjunctive pharmacological therapy in suppressing spontaneous arrhythmias in an attempt to minimize the frequency of device activation also can be assessed by this technique. Although present-generation ICDs are capable of storing electrograms of the spontaneous rhythm resulting in device activation, differentiating supraventricular from ventricular arrhythmias solely on the basis of these recordings can be difficult (222). At the present time, AECG remains a useful adjunct in fine tuning

device function (222), including ensuring that there is no overlap in programmed tachycardia detection rate and the maximum heart rate achieved during daily activity.

Technology remains a moving target (223,224). Devices capable of more robust telemetry capabilities are already under development, and although it is conceivable that future devices implanted for the management of tachyarrhythmias and bradyarrhythmias may be totally self-sufficient in their diagnostic function, at the present time AECG remains a useful adjunct in the evaluation of pacemaker and ICD function.

Indications for AECG to Assess Pacemaker and ICD Function

Class I

1. Evaluation of frequent symptoms of palpitation, syncope, or near syncope to assess device function so as to exclude myopotential inhibition and pacemaker-mediated tachycardia and to assist in the programming of enhanced features such as rate responsiveness and automatic mode switching
2. Evaluation of suspected component failure or malfunction when device interrogation is not definitive in establishing a diagnosis
3. To assess the response to adjunctive pharmacological therapy in patients receiving ICD therapy

Class IIb

1. Evaluation of immediate postoperative pacemaker function after pacemaker or ICD implantation as an alternative or adjunct to continuous telemetric monitoring
2. Evaluation of the rate of supraventricular arrhythmias in patients with implanted defibrillators

Class III

1. Assessment of ICD/pacemaker malfunction when device interrogation, ECG, or other available data (chest radiography, etc) are sufficient to establish an underlying cause/diagnosis
2. Routine follow-up in asymptomatic patients

VIII. MONITORING FOR MYOCARDIAL ISCHEMIA

A. General Considerations

During the past decade, AECG monitoring has been extensively used for detection of myocardial ischemia. Although in the past there were a number of technical limitations that led to inadequate and unreliable evaluation of ST-segment changes, with the recent advent of technological advancements it is now widely accepted that AECG monitoring provides accurate and clinically meaningful information about myocardial ischemia in patients with coronary disease (225-230). A number of well-designed clinical studies have evaluated the prevalence and prognostic significance of myocardial ischemia detected by AECG

monitoring (227,228,230-242). Most of these studies have been conducted in patients with proven CAD, and there is a relative paucity of data regarding the role of AECG monitoring in asymptomatic subjects without known CAD or peripheral vascular disease. There is presently no evidence that AECG monitoring provides reliable information concerning ischemia in asymptomatic subjects without known CAD. Most of the studies that have evaluated the relation between the findings obtained during exercise testing and AECG monitoring demonstrated that ST-segment changes indicative of myocardial ischemia during AECG monitoring are relatively infrequent in patients with no evidence of ischemia during exercise testing (243,244). However, in those with an ischemic response during exercise testing, between 25% and 30% of patients demonstrate ischemia during AECG monitoring. There is a significant correlation between the magnitude of ischemia during the exercise tolerance test and the frequency and duration of ischemia during AECG monitoring (34). However, the strength of the correlation is limited, indicating that the 2 tests are not redundant to characterize coronary patients (34).

Unlike exercise testing, AECG monitoring has the distinct advantage of providing long-term monitoring for myocardial ischemia in the outpatient setting while the patient is performing usual daily activities (226,227), including mental stress (245,246). AECG monitoring is also useful for detection of myocardial ischemia in preoperative risk stratification for patients who cannot exercise because of physical disability, peripheral vascular disease, or advanced lung disease. Ischemia monitoring by AECG can also be helpful for evaluation of patients with anginal syndrome with a negative exercise tolerance test if variant angina is suspected. In addition, AECG monitoring for 24 to 48 hours can provide information regarding the circadian pattern of myocardial ischemia as well as underlying pathophysiological mechanisms responsible for the ischemic episodes during daily life. However, in symptomatic patients, diagnostic accuracy is greater with exercise testing (225).

AECG monitoring has the ability to provide comprehensive evaluation of ischemia for a given patient. A number of studies have documented that as much as 80% of ischemic episodes that occur during daily life are not associated with symptoms and would remain undiagnosed unless evaluated by AECG monitoring (226-230). The results of some studies have also demonstrated that episodes of asymptomatic ischemia during AECG monitoring can be frequently detected in patients with angina pectoris who are receiving antianginal drug therapy and are considered to have adequate control of symptoms (227-230). Such residual ischemia, which would remain undetected without AECG monitoring, has been documented in patients with acute ischemic syndromes (unstable angina and after MI) as well as in patients with stable CAD (227-236).

However, the clinical significance of such residual ischemia is unclear.

B. Prevalence and Predictive Value

The prevalence of myocardial ischemia detected by AECG monitoring in patients with stable CAD and angina pectoris ranges between 20% and 45%, with the highest prevalence demonstrated in patients with more advanced multivessel CAD (227-229,247). The available data from a number of clinical studies have shown that between 30% and 40% of patients with unstable angina and those with a recent MI have evidence of myocardial ischemia during AECG monitoring (230,239-242). A number of these studies have emphasized that between 60% and 80% of ischemic episodes detected by AECG monitoring are not associated with symptoms (225-242). Because of lack of symptoms and/or any patient discomfort, the detection of myocardial ischemia by AECG monitoring would only be of clinical significance if its presence was associated with adverse prognosis. Indeed, a number of recent studies have demonstrated that myocardial ischemia detected by AECG monitoring identifies high-risk patients (230-242,248,249). In patients with stable CAD, the results of studies (Table 10) have shown that the presence of ischemic episodes detected by AECG monitoring is associated with a significantly greater risk of future coronary events and cardiac death (231-238). The results of these studies have also documented that ischemia detected during AECG monitoring is an independent predictor of clinical outcome (when compared with several clinical predictors and ECG variables) (231-238,249). In addition, some recent studies have compared the prognostic value of data obtained during exercise testing with the information available from AECG monitoring, and the results of these studies have demonstrated that ischemia detected by AECG monitoring can provide prognostic information additional to that available from established parameters obtained during exercise testing (233,237,242).

AECG monitoring has also been used for preoperative evaluation (Table 11) of patients with peripheral vascular disease with no clinical evidence of CAD (250-259). Between 10% and 40% of patients referred for major vascular surgery have evidence of ischemia detected by AECG monitoring (250-258). Although the independent prognostic value of ischemia detected by AECG monitoring for postoperative cardiac complications has been reported (Table 12), more recent and larger studies have emphasized that the presence of ischemia detected by AECG monitoring in these patients also predicts a poor long-term prognosis (250-259). However, on the basis of the available data, when feasible, exercise testing alone or with an imaging study remains the preferred test of choice for risk stratification of patients with CAD or for preoperative evaluation. For patients who cannot perform exercise, AECG can be used for further evaluation.

Table 10. Variability of AECG Arrhythmia Monitoring

Author (Reference)	No. of Patients	Inclusion Criteria	Methods	Conclusions
Coronary artery disease Winkle et al (178)	51	AMI within 8 to 11 days, no arrhythmia required	Three consecutive 24-h AECGs	Prevalence of "complex PVCs" increased with duration of recording. Low-frequency events (for example, VT) were poorly reproducible
Pratt et al (13)	88	AMI within 60 days, >10 PVCs/h at baseline	Two 24-h AECGs	95% reduction in PVCs was required to exclude spontaneous variability
CAPS Investigators (179)	100	AMI within 6 to 60 days, ≥ 10 PVCs/h	Repeat AECGs on placebo	37% of patients had >70% PVC suppression at some point
Hypertrophic cardiomyopathy Mulrow et al (14)	16	Nonsustained VT	Two 24-h AECGs	50% had no VT on repeat monitoring
Mixed diagnoses Pratt et al (15)	26	>40 PVCs/h at baseline	Repeat 24-h AECG 1 y after drug withdrawal	50% had a decreased number of PVCs; 65% had a decreased number of pairs; and 83% had decreased VT
Raeder et al (16)	45	History of VF, sustained VT, or nonsustained VT	Two 24-h AECGs	>64% reduction in PVCs and >63% reduction in VT were necessary to exclude random variation
Toivonen (17)	20	"Hospitalized for arrhythmia"	Two AECGs during first week, repeated after 6 to 12 mo	Long term was much worse than short-term reproducibility
Michelson and Morganroth (18)	20	≥ 30 PVCs/h at baseline	Four consecutive 24-h AECGs	>65% reduction in PVCs was needed to show a treatment effect
Pratt et al (19)	100	Nonsustained VT at baseline	Four consecutive 24-h AECGs	There was greater variability in patients with CAD; reductions necessary to exclude random variation were $\geq 78\%$ in PVCs, $\geq 83\%$ in pairs, and >77% in VT
Morganroth et al (20)	15	≥ 30 PVCs/h at baseline	Three consecutive 24-h AECGs	$\geq 83\%$ reduction in PVCs was necessary to show a treatment effect
Reiter et al (180)	119	10 PVCs/h at baseline, suppressed on drug	Repeat 24-h AECG on same therapy	83% met efficacy criteria on both recordings

CAPS indicates Cardiac Arrhythmia Pilot Study; AMI, acute MI; CAD, coronary artery disease; VF, ventricular fibrillation; and VT, ventricular tachycardia. Adapted with permission from DiMarco and Philbrick (12).

Table 11. Studies Defining Incidence and Prognostic Significance of Daily Life Ischemia in Stable CAD

Author (Reference)	No. of Patients	% With AECG Ischemia	End Points	Mean Follow-Up	Event Rates		P	Comments
					With AECG Ischemia	Without Ischemia		
Rocco et al (231)	86	57%	Death, MI, UA, revascularization	12.5 mo	40%	3%	0.003	Patients monitored once off Rx
Tzivoni et al (233)	118	33%	Cardiac death, MI, UA, revascularization	28 mo	51%	20%	<0.001	All patients with previous MI
Deedwania and Carbajal (232)	107	43%	Cardiac death	23 mo	24%	8%	0.02	Monitored on Rx
Raby et al (234)	176	18%	Cardiac death, nonfatal MI	20 mo	38%	7%	<0.0001	Patients with peripheral vascular disease
Yeung et al (236)	138	59%	Death, MI, revascularization	37 mo	56%	42%	0.02	Monitored off Rx
Deedwania and Carbajal (237)	86	45%	Cardiac death	24 mo	23%	4%	<0.008	Monitored on Rx that controlled symptoms
deMarchena et al (235)	50	32%	Cardiac death, MI, UA, revascularization	10 mo	56%	21%	<0.02	All patients monitored on Rx that controlled symptoms
Madjlessi-Simon et al (238)	331	27%	Death, MI, revascularization, or worsening angina	21 mo	33%	17%	0.004	All patients initially treated with a β -blocker

Rx indicates drug therapy; and UA, unstable angina.

C. Role in Therapeutic Evaluation

During the past 5 to 7 years, AECG monitoring has been used for the evaluation of efficacy of anti-ischemic therapy in patients with CAD. The results of these studies have revealed that because of day-to-day variability in ischemic indexes, prolonged AECG monitoring for 48 hours is usually necessary for therapeutic evaluation (26,260). A number of studies have demonstrated that 48-hour AECG monitoring performed at baseline and after institution of therapy can provide reliable evaluation about the anti-ischemic efficacy of the drugs used in patients with CAD (261-270). The results of these studies have provided clinically meaningful information regarding differences in the efficacy of various antianginal drugs and shed further light on the pathophysiological mechanisms of actions of various drugs. Data emerging from randomized clinical trials (Table 13) suggest that suppression of myocardial ischemia as evaluated by AECG monitoring may be associated with improved outcome in patients with CAD (264,268,271). However, large-scale, prospective, randomized clinical trials are needed to confirm these results before definite recommendations can be made.

D. Limitations

It is important to note that ST-segment changes and other repolarization abnormalities can occur for reasons other than myocardial ischemia. These include hyperventilation, hypertension, LV hypertrophy, LV dysfunction, conduction abnormalities, postural changes, tachyarrhythmias, preexcitation, sympathetic nervous system influences, psychotropic drugs, antiarrhythmic drugs, digitalis, alterations in drug levels, and electrolyte abnormalities. Although the possibility of these false-positive changes should not preclude the use of AECG monitoring for detection of myocardial ischemia, it is critical to be aware of these conditions while evaluating the predictive value of ST-segment changes in a given patient. The other potential limitation to the clinical use of AECG monitoring (especially for the evaluation of therapeutic interventions) is the marked day-to-day variability in the frequency and duration of ST depression and ischemic episodes, which makes it difficult to assess the effects of therapy on ischemic indexes recorded during AECG monitoring. This can be partially rectified by performing prolonged (48- to 72-hour) AECG monitoring recordings and assessing similar physical and emotional activities performed by patients during serial monitoring sessions. Because of these complex technical requirements and diagnostic criteria, it is essential that the use of AECG monitoring for detection of myocardial ischemia be restricted to laboratories and personnel specifically trained in this area.

Although ST-segment depression is the most frequently encountered ECG sign of ischemia during AECG monitoring, it should be noted that occasionally one can encounter a period of ST-segment elevation (especially in patients

Table 12. Predictive Value of Preoperative ST Monitoring by AECG for Perioperative Cardiac Events After Vascular Surgery

Author (Reference)	No. of Patients	Patients With Abnormal Test	Criteria for Abnormal Test	Perioperative Events		Event	Comments
				Positive* Test	Negative Test		
Raby et al (250)	176	18	A	10% (3/32)	1% (1/144)	D, MI	24-48 h during ambulation
Pasternack et al (256)	200	39	A	9% (7/78)	2% (2/122)	D, MI	
Mangano et al (252)	144	18	A, B	4% (1/26)	4% (5/118)	D, MI	Immediately before surgery
Fleisher et al (253)	67	24	A, B	13% (2/16)	4% (2/51)	D, MI	Immediately before surgery
McPhail et al (255)	100	34	A	15% (5/34)	6% (4/66)	D, MI	
Kirwin et al (254)	96	9	A	11% (1/9)	16% (14/87)	D, MI	Definition of MI based on enzymes only
Fleisher et al (257)	86	23	A, B	10% (2/20)	3% (2/66)	D, MI	Quantitative monitoring not predictive

A indicates ≥ 1 mm ST-segment depression; B, ≥ 2 mm ST-segment elevation; and D, death.

*Positive predictive value for postoperative cardiac events.

with variant angina or high-grade proximal stenoses) that is indicative of transmural ischemia. Occasionally, changes in T-wave polarity and morphology can be observed during AECG monitoring; however, there are presently no data to suggest that such changes are specific indicators of myocardial ischemia.

Indications for AECG for Ischemia Monitoring

Class I

None

Class IIa

1. Patients with suspected variant angina

Class IIb

1. Evaluation of patients with chest pain who cannot exercise
2. Preoperative evaluation for vascular surgery of patients who cannot exercise

3. Patients with known CAD and atypical chest pain syndrome

Class III

1. Initial evaluation of chest pain patients who are able to exercise
2. Routine screening of asymptomatic subjects

IX. PEDIATRIC PATIENTS

The purposes of AECG monitoring in pediatric patients include 1) the evaluation of symptoms that may be arrhythmia related; 2) risk assessment in patients with cardiovascular disease, with or without symptoms of an arrhythmia; and 3) the evaluation of cardiac rhythm after an intervention such as drug therapy or device implantation. As in adult patients, selection of the method of monitoring (ie, continuous recording versus patient activated) is predicated on the frequency and symptoms of the arrhythmia.

Table 13. Clinical Trials to Assess Effect of Anti-Ischemic Strategies on Prognostic Significance of Daily Life Ischemia

Author (Reference)	No. of Patients	End Points	Follow-Up, y	Event Rate by Treatment Group	P
Pepine et al (264)	306	Death, MI, unstable angina, worsening angina, or revascularization	1	25% placebo 11% atenolol	0.001
Rogers et al (268)	558	Death, MI, revascularization, hospital admission	1	32% angina-guided medical strategy 31% ischemia-guided medical strategy 18% revascularization strategy	0.003
Dargie et al (269)	682	Cardiac death, nonfatal MI, and unstable angina	2	13% atenolol 11% nifedipine 8% combination	NS
		Revascularization, worsening angina		8% atenolol 9% nifedipine SR 3% combination	NS
Von Arnim (270)	520	Death, MI, unstable angina, or revascularization	1	32% for non-100% responders 18% for 100% responders 33% for nifedipine 22% for bisoprolol	0.008 0.03

SR indicates sustained release.

Table 14. Yield of AECG Monitoring for Evaluation of Palpitation in Pediatric Patients With No Structural Heart Disease

Author (Reference)	No. of Patients	Method	Symptoms During Monitoring, n (%)		No Symptoms During Monitoring,† No Arrhythmia, n (%)	Method	Mean No. of Days of Monitoring
			Arrhythmia	No Arrhythmia			
Dick et al (272)	6	E	2 (33)	4 (67)	0	E	
Fyfe et al (273)	41	E	9 (22) (8 SVT)	12 (29)	20 (49)	E	75
Porter et al (274)	25	H	3 (12)	9 (36)	13 (52)	H	1
Goldstein et al (275)	48	E	10 (21) (7 SVT)	15 (31)	23 (48)	E	14-90
Karpawich et al (276)	37	E	10 (27)	27 (73)	0	E	30
Karpawich et al (276)	45	H	0	9 (20)	36 (80)	H	1
Houyel et al (277)	201*	E	24 (12) (23 SVT)	112 (56)	65 (32)	E	85
Total	403		58 (14)	188 (47)	157 (39)		

E indicates patient-activated event recorder; SVT, supraventricular tachycardia; and H, Holter (continuous 24-h recorder).

*Includes 25 patients with heart disease.

†Recognition of asymptomatic arrhythmias limited because event recorder would not be activated by patient.

A. Evaluation of Symptoms

The use of AECG monitoring in pediatric patients for the evaluation of symptoms possibly related to an arrhythmia in the absence of heart disease has been the subject of several reports (272-277). These symptoms include palpitation, syncope or near syncope, and chest pain. Regarding palpitation, a patient-activated recorder is generally recommended because of the paroxysmal nature of the symptom. An arrhythmia, usually supraventricular tachycardia, has been reported to correlate with palpitation in 10% to 15% of young patients, whereas ventricular ectopy or bradycardia is demonstrated in another 2% to 5% (Table 14). By comparison, sinus tachycardia is identified in nearly 50% of young patients with symptoms of palpitation during ambulatory monitoring, whereas 30% to 40% of patients have no symptoms during monitoring. Therefore, one of the primary uses of AECG monitoring in pediatric patients is to exclude an arrhythmia as the cause of palpitation.

The role of AECG monitoring in young patients with transient neurological symptoms (syncope, near syncope, or dizziness) in the absence of structural or functional heart disease is limited (278). The intermittent nature of symptoms results in a low efficacy of 24 to 48 hours of continuous ECG monitoring; conversely, temporary patient incapacitation usually precludes patient-activated recording (279). Continuous ECG monitoring is primarily indicated in pediatric patients with exertional symptoms or those with known heart disease, in whom the presence and significance of an arrhythmia may be increased (278,280).

Chest pain may be evaluated by either continuous or patient-activated ECG monitoring. However, a cardiac cause of chest pain is identified in <5% of pediatric patients (281). Most AECG studies in pediatric patients have reported no yield in the evaluation of chest pain (273,275,281). Therefore the primary role of AECG monitoring in pediatric patients with chest pain may be to exclude rather than to diagnose a cardiac cause. However, although reassuring to the physician, exclusion of an arrhythmia as the cause of

palpitation or chest pain may not alter the patient's perception of a possible cardiovascular problem (282).

B. Evaluation of the Patient With Known Cardiovascular Disease

AECG monitoring is commonly used in the periodic evaluation of pediatric patients with heart disease, with or without symptoms of an arrhythmia. The rationale for this testing is the evolution of disease processes (such as long QT syndromes or hypertrophic cardiomyopathies), growth of patients and the need to adjust medication dosages, and the progressive onset of late arrhythmias after surgery for congenital heart defects.

The use of AECG monitoring for periodic evaluation of patients with prior surgical treatment of congenital heart disease must be based on consideration of the type of defect, ventricular function, and risk of late postoperative arrhythmias. For example, uncomplicated repairs of atrial or ventricular septal defects are associated with a low incidence of late postoperative arrhythmias (283). Conversely, complex repairs or those with residual hemodynamic abnormalities have a well-recognized incidence of late-onset atrial and ventricular arrhythmias (284,285). Although the significance of arrhythmias in these patients remains controversial, high-grade ambulatory ventricular ectopy associated with ventricular dysfunction does appear to identify patients at an increased risk of late sudden death (286,287). Complex arrhythmias detected in these patients by AECG may indicate the need for further investigation, even in the absence of overt symptoms (288).

Periodic AECG monitoring for young patients with hypertrophic or dilated cardiomyopathies or the long QT syndromes is recommended because of the progression of these diseases and the need to adjust medication doses with growth. The risk of sudden death with these diseases is much greater in pediatric patients than adults, with sudden death a first symptom in 9% to 15% of patients (289,290). One primary role of AECG monitoring is to identify occult

arrhythmias, which may indicate the need for reevaluation of therapy in an asymptomatic patient. However, the absence of an arrhythmia during monitoring does not necessarily indicate a low risk of sudden death.

AECG monitoring has a limited role for establishing a diagnosis of long QT syndrome in patients with borderline QT prolongation. This is due to differences in sampling, signal filtering, and recording methods compared with conventional ECG (291).

AECG monitoring may be used to identify asymptomatic patients with congenital complete AV block at increased risk for sudden arrhythmic events and who thus may benefit from prophylactic pacemaker implantation (292). Conversely, routine AECG evaluation of asymptomatic patients with preexcitation syndromes (Wolff-Parkinson-White) has not been demonstrated to define patients at risk for sudden arrhythmic death (293).

Unexplained syncope or cardiovascular collapse in patients with cardiovascular disease generally requires in-hospital continuous ECG monitoring, with an invasive evaluation when the cause of the event is uncertain (294). However, if a cause cannot be established by invasive methods, AECG monitoring may be used for subsequent evaluation to evaluate for both transient bradyarrhythmias and tachyarrhythmias (295).

C. Other Medical Conditions

Arrhythmias have become increasingly recognized in young patients with a number of diverse medical conditions. These include Duchenne or Becker muscular dystrophy, myotonic dystrophy, and patients who are survivors of childhood malignancies. Limited data would suggest that AECG monitoring may be indicated in these patients in the presence of symptoms compatible with an arrhythmia because of the potential for both ventricular arrhythmias and progressive conduction system disease (296-299).

D. Evaluation After Therapy or Intervention

AECG monitoring is useful to evaluate both beneficial and potentially adverse responses to pharmacological therapy in pediatric patients (300,301). The limitations of AECG monitoring as the result of day-to-day variance in ventricular ectopy have been discussed in Section 6. Additional indications for AECG monitoring include the evaluation of symptoms in patients with pacemakers or after radiofrequency catheter ablation or heart surgery, particularly when complicated by transient AV block (302,303). Specific considerations in the use of AECG monitoring for assessment of pacemaker function are addressed in Section 7. AECG monitoring is also indicated for the evaluation of cardiac rhythm after treatment of incessant tachyarrhythmias, which have been associated with progressive ventricular dysfunction (304).

Indications for AECG Monitoring in Pediatric Patients

Class I

1. Syncope, near syncope, or dizziness in patients with recognized heart disease, previously documented arrhythmia, or pacemaker dependency
2. Syncope or near syncope associated with exertion when the cause is not established by other methods
3. Evaluation of patients with hypertrophic or dilated cardiomyopathies
4. Evaluation of possible or documented long QT syndromes
5. Palpitation in the patient with prior surgery for congenital heart disease and significant residual hemodynamic abnormalities
6. Evaluation of antiarrhythmic drug efficacy during rapid somatic growth
7. Asymptomatic congenital complete AV block, non-paced

Class IIa

1. Syncope, near syncope, or sustained palpitation in the absence of a reasonable explanation and where there is no overt clinical evidence of heart disease
2. Evaluation of cardiac rhythm after initiation of an antiarrhythmic therapy, particularly when associated with a significant proarrhythmic potential
3. Evaluation of cardiac rhythm after transient AV block associated with heart surgery or catheter ablation
4. Evaluation of rate-responsive or physiological pacing function in symptomatic patients

Class IIb

1. Evaluation of asymptomatic patients with prior surgery for congenital heart disease, particularly when there are either significant or residual hemodynamic abnormalities, or a significant incidence of late postoperative arrhythmias
2. Evaluation of the young patient (<3 years) with a prior tachyarrhythmia to determine if unrecognized episodes of the arrhythmia recur
3. Evaluation of the patient with a suspected incessant atrial tachycardia
4. Complex ventricular ectopy on ECG or exercise test

Class III

1. Syncope, near syncope, or dizziness when a noncardiac cause is present
2. Chest pain without clinical evidence of heart disease
3. Routine evaluation of asymptomatic individuals for athletic clearance
4. Brief palpitation in the absence of heart disease
5. Asymptomatic Wolff-Parkinson-White syndrome

STAFF

American College of Cardiology

Christine W. McEntee, Executive Vice President
Mary Anne Elma, Manager, Practice Guidelines
Kimberly Harris, Manager, Practice Guidelines
Gwen C. Pigman, MLS, Assistant Director, On-Line and
Library Services

American Heart Association

Office of Scientific Affairs

Rodman D. Starke, MD, FACC, Senior Vice President for
Science and Medicine
Kathryn A. Taubert, PhD, Senior Scientist

REFERENCES

1. Knoebel SB, Crawford MH, Dunn MI, et al. Guidelines for ambulatory electrocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Subcommittee on Ambulatory Electrocardiography). *J Am Coll Cardiol* 1989;13:249-58.
2. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA Guidelines for the Clinical Application of Echocardiography: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Clinical Application of Echocardiography). Developed in Collaboration with the American Society of Echocardiography. *Circulation* 1997;95:1686-744.
3. Association for the Advancement of Medical Instrumentation. American national standard: ambulatory electrocardiographs. Arlington, VA: ANSI/AAMI; 1994. EC 38.
4. Bragg-Remschel DA, Anderson CM, et al. Frequency response characteristics of ambulatory ECG monitoring systems and their implications for ST segment analysis. *Am Heart J* 1982;103:20-31.
5. Shook TL, Balke CW, Kotilainen PW, et al. Comparison of amplitude-modulated (direct) and frequency-modulated ambulatory techniques for recording ischemic electrocardiographic changes. *Am J Cardiol* 1987;60:895-900.
6. Nearing BD, Stone PH, Verrier RL. Frequency response characteristics required for detection of T-wave alternans during ambulatory ECG monitoring. *Ann Noninvas Electrocardiol* 1996;1:103-12.
7. Phadke K, Mulcahy D, Fox K. Clinical validation of four solid state ambulatory monitoring devices in detecting shift of the ST segment. *Int J Cardiol* 1991;33:445-6.
8. Lanza GA, Lucente M, Rebuzzi AG, et al. Accuracy in clinical arrhythmia detection of a real-time Holter system (Oxford Medilog 4500). *J Electrocardiol* 1990;23:301-6.
9. Kennedy HL, et al. Limitations of ambulatory ECG real-time analysis for ventricular and supraventricular arrhythmia accuracy detected by clinical evaluation. *Am J Noninvas Cardiol* 1992;6:137-46.
10. Lanza GA, Mascallanti M, Piacentino M, et al. Usefulness of a third Holter lead for detection of myocardial ischemia. *Am J Cardiol* 1994;74:1216-9.
11. Seeberger MD, Moerlen J, Skarvan K, et al. The inverse Nehb J lead increases the sensitivity of Holter electrocardiographic monitoring for detecting myocardial ischemia. *Am J Cardiol* 1997;80:1-5.
12. DiMarco JP, Philbrick JT. Use of ambulatory electrocardiographic (Holter) monitoring. *Ann Intern Med* 1990;113:53-68.
13. Pratt CM, Theroux P, Slymen D, et al. Spontaneous variability of ventricular arrhythmias in patients at increased risk for sudden death after acute myocardial infarction: consecutive ambulatory electrocardiographic recordings of 88 patients. *Am J Cardiol* 1987;59:278-83.
14. Mulrow JP, Healy MJ, McKenna WJ. Variability of ventricular arrhythmias in hypertrophic cardiomyopathy and implications for treatment. *Am J Cardiol* 1986;58:615-8.
15. Pratt CM, Delclos G, Wierman AM, et al. The changing baseline of complex ventricular arrhythmias: a new consideration in assessing long-term antiarrhythmic drug therapy. *N Engl J Med* 1985;313:1444-9.
16. Raeder EA, Hohnloser SH, Graboy TB, et al. Spontaneous variability and circadian distribution of ectopic activity in patients with malignant ventricular arrhythmia. *J Am Coll Cardiol* 1988;12:656-61.
17. Toivonen L. Spontaneous variability in the frequency of ventricular premature complexes over prolonged intervals and implications for antiarrhythmic treatment. *Am J Cardiol* 1987;60:608-12.
18. Michelson EL, Morganroth J. Spontaneous variability of complex ventricular arrhythmias detected by long-term electrocardiographic recording. *Circulation* 1980;61:690-5.
19. Pratt CM, Slymen DJ, Wierman AM, et al. Analysis of the spontaneous variability of ventricular arrhythmias: consecutive ambulatory electrocardiographic recordings of ventricular tachycardia. *Am J Cardiol* 1985;56:67-72.
20. Morganroth J, Michelson EL, Horowitz LN, et al. Limitations of routine long-term electrocardiographic monitoring to assess ventricular ectopic frequency. *Circulation* 1978;58:408-14.
21. Anastasiou-Nana MI, Menlove RL, Nanas JN, et al. Changes in spontaneous variability of ventricular ectopic activity as a function of time in patients with chronic arrhythmias. *Circulation* 1988;78:286-95.
22. Schmidt G, Ulm K, Barthel P, et al. Spontaneous variability of simple and complex ventricular premature contractions during long time intervals in patients with severe organic heart disease. *Circulation* 1988;78:296-301.
23. Bass EB, Curtiss EI, Arena VC, et al. The duration of Holter monitoring in patients with syncope: is 24 hours enough? *Arch Intern Med* 1990;150:1073-8.
24. Deanfield JE, Maseri A, Selwyn AP, et al. Myocardial ischaemia during daily life in patients with stable angina: its relation to symptoms and heart rate changes. *Lancet* 1983;2:753-8.
25. Tzivoni D, Gavish A, Benhorin J, et al. Day-to-day variability of myocardial ischemic episodes in coronary artery disease. *Am J Cardiol* 1987;60:1003-5.
26. Nabel EG, Barry J, Rocco MB, et al. Variability of transient myocardial ischemia in ambulatory patients with coronary artery disease. *Circulation* 1988;78:60-7.
27. Nademanee K, Christenson PD, Intarachot V, et al. Variability of indexes for myocardial ischemia: a comparison of exercise treadmill test, ambulatory electrocardiographic monitoring and symptoms of myocardial ischemia. *J Am Coll Cardiol* 1989;13:574-9.
28. Celermajer DS, Spiegelhalter DJ, Deanfield M, et al. Variability of episodic ST segment depression in chronic stable angina: implications for individual and group trials of therapeutic efficacy. *J Am Coll Cardiol* 1994;23:66-73.
29. Andrews TC, Fenton T, Toyosaki N, et al. Subsets of ambulatory myocardial ischemia based on heart rate activity: circadian distribution and response to anti-ischemic medication: the Angina and Silent Ischemia Study Group (ASIS). *Circulation* 1993;88:92-100.
30. Stone PH, McMahan RP, Andrews TC, et al. Heart rate during daily activities and reproducibility of ischemia using ambulatory ECG monitoring: the Psychophysiological Investigations of Myocardial Ischemia (PIMI) study (abstr). *Circulation* 1996;94 Suppl I:I-78.
31. Roelke M, Ruskin JM. Arrhythmias detected with implantable cardioverter-defibrillators. In: Moss AJ, editor. *Noninvasive electrocardiography: clinical aspects of Holter monitoring*. Philadelphia, PA: WB Saunders Co Ltd, 1996:93-105.
32. Coumel P, Thomas O, Leenhardt A. Holter functions of the implantable cardioverter defibrillator: what is still missing? *Pacing Clin Electrophysiol* 1995;18:560-8.
33. Pratt CM, Eaton T, Francis M, et al. Ambulatory electrocardiographic recordings: the Holter monitor. *Curr Probl Cardiol* 1988;13:517-86.
34. Stone PH, Chaitman BR, McMahan RP, et al. The Asymptomatic Cardiac Ischemia Pilot (ACIP) Study: relationship between exercise-induced and ambulatory ischemia in patients with stable coronary disease. *Circulation* 1996;94:1537-44.
35. Cohn PF, Kannel WB. Recognition, pathogenesis, and management options in silent coronary artery disease. *Circulation* 1987;75:III1.
36. Algra A, Tijssen JG, Roelandt JR, et al. QT interval variables from 24 hour electrocardiography and the 2 year risk of sudden death. *Br Heart J* 1993;70:43-8.
37. Zareba W. Ventricular repolarization measures: QT interval, Rtm interval or T wave loop morphology? *Ann Noninvas Electrocardiol* 1997;2:101-3.
38. Schneider AE, Plewan A, Schmitt C, et al. The signal-averaged

- ECG obtained by a new digital Holter recording system. *Ann Noninvas Electrocardiol* 1996;1:379-85.
39. Bigger JT. Spectral analysis of R-R variability to evaluate autonomic physiology and pharmacology and to predict cardiovascular outcomes in humans. In: Zipes DP, editor. *Cardiac electrophysiology: from cell to bedside*. 2nd ed. Philadelphia, PA: WB Saunders Co, 1995:1151-70.
 40. Malik M, Camm AJ. Components of heart rate variability: what they really mean and what we really measure. *Am J Cardiol* 1993;72:821-2.
 41. Stein KS, Bosner MD, Kleiger RE, et al. Heart rate variability: a measure of cardiac autonomic tone. *Am Heart J* 1994;127:1376-81.
 42. Pagani M, Lombardi F, Malliani A. Heart rate variability: disagreement on the markers of sympathetic and parasympathetic activities. *J Am Coll Cardiol* 1993;22:951-3.
 43. Akselrod S, Gordon D, Ubel FA, et al. Power spectrum analysis of heart rate fluctuation: a quantitative probe of beat-to-beat cardiovascular control. *Science* 1981;213:220-2.
 44. Pomeranz B, Macaulay RJ, Caudill MA, et al. Assessment of autonomic function in humans by heart rate spectral analysis. *Am J Physiol* 1985;248:H151-3.
 45. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Heart rate variability: standards of measurement, physiological interpretation, and clinical use. *Circulation* 1996;93:1043-65.
 46. Rinoli T, Porges SW. Inferential and descriptive influences on measures of respiratory sinus arrhythmia: sampling rate, R-wave trigger accuracy, and variance estimates. *Psychophysiology* 1997;34:613-21.
 47. Friesen GM, Jannett TC, Jadallah MA, et al. A comparison of the noise sensitivity of nine QRS detection algorithms. *IEEE Trans Biomed Eng* 1990;37:85-98.
 48. Bartoli F, Baselli G, Cerutti S. Application of identification and linear filtering algorithms to the R-R interval measurements. In: *Computers in cardiology*. Silver Spring, Md: IEEE Computer Society, 1982:485-8.
 49. Merri M, Farden DC, Mottley JG, et al. Sampling frequency of the electrocardiogram for spectral analysis of the heart rate variability. *IEEE Trans Biomed Eng* 1990;37:99-106.
 50. Cheung MN. Detection of and recovery from errors in cardiac interbeat intervals. *Psychophysiology* 1981;18:341-6.
 51. Berntson GG, Quigley KS, Jang JF, et al. An approach to artifact identification: application to heart period data. *Psychophysiology* 1990;27:586-98.
 52. Linden W, Estrin R. Computerized cardiovascular monitoring: method and data. *Psychophysiology* 1988;25:227-34.
 53. Saul JP, Arai Y, Berger RD, et al. Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. *Am J Cardiol* 1988;61:1292-9.
 54. Kleiger RE, Bigger JT, Bosner MS, et al. Stability over time of variables measuring heart rate variability in normal subjects. *Am J Cardiol* 1991;68:626-30.
 55. Umetani K, Singer D, McCraty R, et al. Twenty-four hour time domain heart rate variability and heart rate: relations to age and gender over 9 decades. *J Am Coll Cardiol* 1998;31:593-601.
 56. Bigger JT, Fleiss JL, Steinman RC, et al. Correlations among time and frequency domain measures of heart period variability 2 weeks after acute myocardial infarction. *Am J Cardiol* 1992;69:891-8.
 57. Stein PK, Rottman JN, Kleiger RE. Time domain measure of heart rate variability as surrogates for frequency domain measures in stable congestive heart failure patients and normals (abstr). *Circulation* 1994;90 Suppl I:I-331.
 58. Diamond TH, Smith R, Myburgh DP. Holter monitoring: a necessity for the evaluation of palpitations. *S Afr Med J* 1983;63:5-7.
 59. Kapoor WN, Cha R, Peterson JR, et al. Prolonged electrocardiographic monitoring in patients with syncope: importance of frequent or repetitive ventricular ectopy. *Am J Med* 1987;82:20-8.
 60. Kennedy HL, Underhill SJ. Frequent or complex ventricular ectopy in apparently healthy subjects: a clinical study of 25 cases. *Am J Cardiol* 1976;38:141-8.
 61. Rafferty EB, Cashman PM. Long-term recording of the electrocardiogram in a normal population. *Postgrad Med J* 1976;52 Suppl 7:32-8.
 62. Glasser SP, Clark PI, Applebaum HJ. Occurrence of frequent complex arrhythmias detected by ambulatory monitoring: findings in an apparently healthy asymptomatic elderly population. *Chest* 1979;75:565-8.
 63. Kostis JB, McCrone K, Moreyra AE, et al. Premature ventricular complexes in the absence of identifiable heart disease. *Circulation* 1981;63:1351-6.
 64. Linzer M, Yang EH, Estes NA, et al. Diagnosing syncope, I: value of history, physical examination, and electrocardiography: Clinical Efficacy Assessment Project of the American College of Physicians. *Ann Intern Med* 1997;126:989-96.
 65. Linzer M, Yang EH, Estes NA, et al. Diagnosing syncope, II: unexplained syncope: Clinical Efficacy Assessment Project of the American College of Physicians. *Ann Intern Med* 1997;127:76-86.
 66. Gibson TC, Heitzman MR. Diagnostic efficacy of 24-hour electrocardiographic monitoring for syncope. *Am J Cardiol* 1984;53:1013-7.
 67. Kala R, Viitasalo MT, Toivonen L, et al. Ambulatory ECG recording in patients referred because of syncope or dizziness. *Acta Med Scand Suppl* 1982;668:13-9.
 68. Zeldis SM, Levine BJ, Michelson EL, et al. Cardiovascular complaints: correlation with cardiac arrhythmias on 24-hour electrocardiographic monitoring. *Chest* 1980;78:456-61.
 69. Clark PI, Glasser SP, Spoto E Jr. Arrhythmias detected by ambulatory monitoring: lack of correlation with symptoms of dizziness and syncope. *Chest* 1980;77:722-5.
 70. Bhandari AK, Anderson JL, Gilbert EM, et al. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study: the Flecainide Supraventricular Tachycardia Study Group. *Am Heart J* 1992;124:381-6.
 71. Kinlay S, Leitch JW, Neil A, et al. Cardiac event recorders yield more diagnoses and are more cost-effective than 48-hour Holter monitoring in patients with palpitations: a controlled clinical trial. *Ann Intern Med* 1996;124:16-20.
 72. Schmidt SB, Jain AC. Diagnostic utility of memory equipped transtelephonic monitors. *Am J Med Sci* 1988;296:299-302.
 73. Linzer M, Pritchett EL, Pontinen M, et al. Incremental diagnostic yield of loop electrocardiographic recorders in unexplained syncope. *Am J Cardiol* 1990;66:214-9.
 74. Shimada M, Akaishi M, Asakura K, et al. Usefulness of the newly developed transtelephonic electrocardiogram and computer-supported response system. *J Cardiol* 1996;27:211-7.
 75. Kus T, Nadeau R, Costi P, et al. Comparison of the diagnostic yield of Holter versus transtelephonic monitoring. *Can J Cardiol* 1995;11:891-4.
 76. Murdock CJ, Klein GJ, Yee R, et al. Feasibility of long-term electrocardiographic monitoring with an implanted device for syncope diagnosis. *Pacing Clin Electrophysiol* 1990;13:1374-8.
 77. Leitch J, Klein G, Yee R, et al. Feasibility of an implantable arrhythmia monitor. *Pacing Clin Electrophysiol* 1992;15:2232-5.
 78. Boudoulas H, Schaal SF, Lewis RP, et al. Superiority of 24-hour outpatient monitoring over multi-stage exercise testing for the evaluation of syncope. *J Electrocardiol* 1979;12:103-8.
 79. Jonas S, Klein I, Dimant J. Importance of Holter monitoring in patients with periodic cerebral symptoms. *Ann Neurol* 1977;1:470-4.
 80. Page RL, Wilkinson WE, Clair WK, et al. Asymptomatic arrhythmias in patients with symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia. *Circulation* 1994;89:224-7.
 81. Clair WK, Wilkinson WE, McCarthy EA, et al. Spontaneous occurrence of symptomatic paroxysmal atrial fibrillation and paroxysmal supraventricular tachycardia in untreated patients. *Circulation* 1993;87:1114-22.
 82. Kessler DK, Kessler KM. Is ambulatory electrocardiography useful in the evaluation of patients with recent stroke? *Chest* 1995;107:916-8.
 83. Assayag P, Chailley O, Lehner JP, et al. Contribution of sequential voluntary ambulatory monitoring in the diagnosis of arrhythmia: a multicenter study of 1287 symptomatic patients. *Arch Mal Coeur Vaiss* 1992;85:281-6.
 84. Bigger JT Jr, Fleiss JL, Kleiger R, et al. The relationships among ventricular arrhythmias, left ventricular dysfunction, and mortality in the 2 years after myocardial infarction. *Circulation* 1984;69:250-8.
 85. Multicenter Post-infarction Research Group. Risk stratification and survival after myocardial infarction. *N Engl J Med* 1983;309:331-6.

86. McClements BM, Adgey AA. Value of signal-averaged electrocardiography, radionuclide ventriculography, Holter monitoring and clinical variables for prediction of arrhythmic events in survivors of acute myocardial infarction in the thrombolytic era. *J Am Coll Cardiol* 1993;21:1419-27.
87. Hohnloser SH, Franck P, Klingenhoben T, et al. Open infarct artery, late potentials, and other prognostic factors in patients after acute myocardial infarction in the thrombolytic era: a prospective trial. *Circulation* 1994;90:1747-56.
88. Cairns JA, Connolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations: CAMIAT, Canadian Amiodarone Myocardial Infarction Arrhythmia Trial Investigators. *Lancet* 1997;349:675-82.
89. Farrell TG, Bashir Y, Cripps T, et al. Risk stratification for arrhythmic events in postinfarction patients based on heart rate variability, ambulatory electrocardiographic variables and the signal-averaged electrocardiogram. *J Am Coll Cardiol* 1991;18:687-97.
90. El-Sherif N, Denes P, Katz R, et al. Definition of the best prediction criteria of the time domain signal-averaged electrocardiogram for serious arrhythmic events in the postinfarction period: the Cardiac Arrhythmia Suppression Trial/Signal-Averaged Electrocardiogram (CAST/SAECG) Substudy Investigators. *J Am Coll Cardiol* 1995; 25:908-14.
91. Gomes JA, Winters SL, Martinson M, et al. The prognostic significance of quantitative signal-averaged variables relative to clinical variables, site of myocardial infarction, ejection fraction and ventricular premature beats: a prospective study. *J Am Coll Cardiol* 1989;13:377-84.
92. Davis BR, Friedman LM, Lichstein E. The prognostic value of the duration of the ambulatory electrocardiogram after myocardial infarction. *Med Decis Making* 1988;8:9-18.
93. Davis BR, Friedman LM, Lichstein E. Are 24 hours of ambulatory ECG monitoring necessary for a patient after infarction? *Am Heart J* 1988;115:83-91.
94. Mukharji J, Rude RE, Poole WK, et al. Risk factors for sudden death after acute myocardial infarction: 2-year follow-up. *Am J Cardiol* 1984;54:31-6.
95. Kleiger RE, Miller JP, Bigger JT, et al. Decreased heart rate variability and its association with increased mortality after acute myocardial infarction. *Am J Cardiol* 1987;59:256-62.
96. Kostis JB, Byington R, Friedman LM, et al. Prognostic significance of ventricular ectopic activity in survivors of acute myocardial infarction. *J Am Coll Cardiol* 1987;10:231-42.
97. Kuchar DL, Thorburn CW, Sammel NL. Prediction of serious arrhythmic events after myocardial infarction: signal-averaged electrocardiogram, Holter monitoring and radionuclide ventriculography. *J Am Coll Cardiol* 1987;9:531-8.
98. de Cock CC, Visser FC, van Eenige MJ, et al. Independent prognostic value of supraventricular arrhythmias on 24-h ambulatory monitoring following myocardial infarction. *Eur Heart J* 1991;12: 1070-5.
99. Wilson AC, Kostis JB. The prognostic significance of very low frequency ventricular ectopic activity in survivors of acute myocardial infarction: BHAT Study Group. *Chest* 1992;102:732-6.
100. Pedretti R, Etrio MD, Laporta A, et al. Prediction of late arrhythmic events after acute myocardial infarction from combined use of noninvasive prognostic variables and inducibility of sustained monomorphic ventricular tachycardia. *Am J Cardiol* 1993;71:1131-41.
101. Denes P, Gillis AM, Pawitan Y, et al. Prevalence, characteristics and significance of ventricular premature complexes and ventricular tachycardia detected by 24-hour continuous electrocardiographic recording in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. *Am J Cardiol* 1991;68:887-96.
102. Dittrich H, Gilpin E, Nicod P, et al. Acute myocardial infarction in women: influence of gender on mortality and prognostic variables. *Am J Cardiol* 1988;62:1-7.
103. Moss AJ, Carleen E, the Multicenter Postinfarction Research Group. Gender differences in the mortality risk associated with ventricular arrhythmias after myocardial infarction. In: Eaker E, Packard B, Wenger NK, et al, editors. *Coronary heart disease in women*. New York: Haymarket Doyma, Inc, 1986:204-7.
104. Bigger JT, Fleiss JL, Steinman RC, et al. Frequency domain measures of heart period variability and mortality after myocardial infarction. *Circulation* 1992;85:164-71.
105. Zhang YZ, Wang SW, Hu DY, et al. Prediction of life-threatening arrhythmia in patients after myocardial infarction by late potentials, ejection fraction and Holter monitoring. *Jpn Heart J* 1992;33:15-23.
106. La Rovere MT, Bigger JT Jr, Marcus FI, et al. Baroreflex sensitivity and heart rate variability in prediction of total cardiac mortality after myocardial infarction: ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. *Lancet* 1998;351:478-84.
107. Odemuyiwa O, Malik M, Farrell T, et al. Comparison of the predictive characteristics of heart rate variability index and left ventricular ejection fraction for all-cause mortality, arrhythmic events and sudden death after acute myocardial infarction. *Am J Cardiol* 1991;68:434-9.
108. Bigger JT, Fleiss JL, Rolnitzky LM, et al. Frequency domain measures of heart period variability to assess risk late after myocardial infarction. *J Am Coll Cardiol* 1993;21:729-36.
109. Faber TS, Staunton A, Hnatkova K, et al. Stepwise strategy of using short- and long-term heart rate variability for risk stratification after myocardial infarction. *Pacing Clin Electrophysiol* 1996;19:1845-51.
110. Fei L, Malik M. Short-term and long-term assessment of heart rate variability for postinfarction risk stratification. In: Malik M, Camm AJ, editors. *Heart rate variability*. Armonk, NY: Futura Publishing Co, Inc; 1995:341-6.
111. Malik M, Camm AJ. Significance of long term components of heart rate variability for the further prognosis after acute myocardial infarction. *Cardiovasc Res* 1990;24:793-803.
112. Bigger JT, Fleiss JL, Rolnitzky LM, et al. The ability of several short-term measures of RR variability to predict mortality after myocardial infarction. *Circulation* 1993;88:927-34.
113. Moss AJ, Hall WJ, Cannon DS, et al. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia: Multicenter Automatic Defibrillator Implantation Trial Investigators. *N Engl J Med* 1996;335:1933-40.
114. Sim I, McDonald KM, Lavori PW, et al. Quantitative overview of randomized trials of amiodarone to prevent sudden cardiac death. *Circulation* 1997;96:2823-9.
115. Huang SK, Messer JV, Denes P. Significance of ventricular tachycardia in idiopathic dilated cardiomyopathy: observations in 35 patients. *Am J Cardiol* 1983;51:507-12.
116. Kron J, Hart M, Schual-Berke S, et al. Idiopathic dilated cardiomyopathy: role of programmed electrical stimulation and Holter monitoring in predicting those at risk of sudden death. *Chest* 1988;93: 85-90.
117. Holmes J, Kubo SH, Cody RJ, et al. Arrhythmias in ischemic and nonischemic dilated cardiomyopathy: prediction of mortality by ambulatory electrocardiography. *Am J Cardiol* 1985;55:146-51.
118. Unverferth DV, Magorien RD, Moeschberger ML, et al. Factors influencing the 1-year mortality of dilated cardiomyopathy. *Am J Cardiol* 1984;54:147-52.
119. Pelliccia F, Gallo P, Cianfrocca C, et al. Relation of complex ventricular arrhythmias to presenting features and prognosis in dilated cardiomyopathy. *Int J Cardiol* 1990;29:47-54.
120. Ikegawa T, Chino M, Hasegawa H, et al. Prognostic significance of 24-hour ambulatory electrocardiographic monitoring in patients with dilative cardiomyopathy: a prospective study. *Clin Cardiol* 1987;10: 78-82.
121. Szabo BM, van Veldhuisen DJ, Crijns HJ, et al. Value of ambulatory electrocardiographic monitoring to identify risk of sudden death in patients with left ventricular dysfunction and heart failure. *Eur Heart J* 1994;15:928-33.
122. Doval HC, Nul DR, Grancelli HO, et al. Nonsustained ventricular tachycardia in severe heart failure: independent marker of increased mortality due to sudden death: GESICA-GEMA Investigators. *Circulation* 1996;94:3198-203.
123. Kienzle MG, Ferguson DW, Birkett CL, et al. Clinical hemodynamic and sympathetic neural correlates of heart rate variability in congestive heart failure. *Am J Cardiol* 1992;69:761-7.
124. Casolo G, Balli E, Taddei T, et al. Decreased spontaneous heart rate variability in congestive heart failure. *Am J Cardiol* 1989;64:1162-7.
125. Townend JN, West JN, Davies MK, et al. Effect of quinapril on blood pressure and heart rate in congestive heart failure. *Am J Cardiol* 1992;69:1587-90.

126. Binkley PF, Haas GJ, Starling RC, et al. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. *J Am Coll Cardiol* 1993;21:655-61.
127. Hoffmann J, Grimm W, Menz V, et al. Heart rate variability and major arrhythmic events in patients with idiopathic dilated cardiomyopathy. *Pacing Clin Electrophysiol* 1996;19:1841-4.
128. Hohnloser SH, Klingenhoben T, van de Loo A, et al. Reflex versus tonic vagal activity as a prognostic parameter in patients with sustained ventricular tachycardia or ventricular fibrillation. *Circulation* 1994;89:1068-73.
129. Fei L, Keeling PJ, Gill JS, et al. Heart rate variability and its relation to ventricular arrhythmias in congestive heart failure. *Br Heart J* 1994;71:322-8.
130. Ponikowski P, Anker SD, Chua TP, et al. Depressed heart rate variability as an independent predictor of death in chronic congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. *Am J Cardiol* 1997;79:1645-50.
131. Fauchier L, Babuty D, Cosnay P, et al. Heart rate variability in idiopathic dilated cardiomyopathy: characteristics and prognostic value. *J Am Coll Cardiol* 1997;30:1009-14.
132. Jiang W, Hathaway WR, McNulty S, et al. Ability of heart rate variability to predict prognosis in patients with advanced congestive heart failure. *Am J Cardiol* 1997;80:808-11.
133. Maron BJ, Savage DD, Wolfson JK, et al. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. *Am J Cardiol* 1981;48:252-7.
134. Fananapazir L, Chang AC, Epstein SE, et al. Prognostic determinants in hypertrophic cardiomyopathy. *Circulation* 1992;86:730-40.
135. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. *Br Heart J* 1985;53:412-6.
136. Counihan PJ, Fei L, Bashir Y, et al. Assessment of heart rate variability in hypertrophic cardiomyopathy: association with clinical and prognostic features. *Circulation* 1993;88:1682-90.
137. Marangoni S, Scavini S, Mai R, et al. Heart rate variability assessment in patients with mitral valve prolapse syndrome. *Am J Noninvas Cardiol* 1993;7:210-4.
138. Stein KM, Borer JS, Hochreiter C, et al. Prognostic value and physiological correlates of heart rate variability in chronic severe mitral regurgitation. *Circulation* 1993;88:127-35.
139. Hoffmann A, Burckhardt D. Patients at risk for cardiac death late after aortic valve replacement. *Am Heart J* 1990;120:1142-7.
140. Ewing DJ, Campbell IW, Clarke BF. The natural history of diabetic autonomic neuropathy. *Q J Med* 1980;49:95-108.
141. Malpas SC, Maling TJ. Heart-rate variability and cardiac autonomic function in diabetes. *Diabetes* 1990;39:1177-81.
142. Ewing DJ, Neilson JM, Shapiro CM, et al. Twenty four hour heart rate variability: effects of posture, sleep, and time of day in healthy controls and comparison with bedside tests of autonomic function in diabetic patients. *Br Heart J* 1991;65:239-44.
143. Pagani M, Malfatto G, Pierini S, et al. Spectral analysis of heart rate variability in the assessment of autonomic diabetic neuropathy. *J Auton Nerv Syst* 1988;23:143-53.
144. Bellavere F, Balzani I, De Masi G, et al. Power spectral analysis of heart-rate variations improves assessment of diabetic cardiac autonomic neuropathy. *Diabetes* 1992;41:633-40.
145. Blumberg A, Hausemann M, Strub B, et al. Cardiac arrhythmias in patients on maintenance hemodialysis. *Nephron* 1983;33:91-5.
146. Abe S, Yoshizawa M, Nakanishi N, et al. Electrocardiographic abnormalities in patients receiving hemodialysis. *Am Heart J* 1996;131:1137-44.
147. D'Elia JA, Weinrauch LA, Gleason RE, et al. Application of the ambulatory 24-hour electrocardiogram in the prediction of cardiac death in dialysis patients. *Arch Intern Med* 1988;148:2381-5.
148. Lown B, Wolfe M. Approaches to sudden death from coronary artery disease. *Circulation* 1971;44:130-42.
149. Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram: prevalence, incidence, and mortality in the Framingham study. *Ann Intern Med* 1969;71:89-105.
150. Messerli FH, Ventura HO, Elizardi DJ, et al. Hypertension and sudden death: increased ventricular ectopic activity in left ventricular hypertrophy. *Am J Med* 1984;77:18-22.
151. McLenachan JM, Henderson E, Morris KI, et al. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. *N Engl J Med* 1987;317:787-92.
152. Siegel D, Cheitlin MD, Black DM, et al. Risk of ventricular arrhythmias in hypertensive men with left ventricular hypertrophy. *Am J Cardiol* 1990;65:742-7.
153. Ferrara N, Furgi G, Longobardi G, et al. Relation between age, left ventricular mass and ventricular arrhythmias in patients with hypertension. *J Hum Hypertens* 1995;9:581-7.
154. Kannel WB, Dannenberg AL, Levy D. Population implications of electrocardiographic left ventricular hypertrophy. *Am J Cardiol* 1987;60:851-931.
155. Levy D, Anderson KM, Savage DD, et al. Risk of ventricular arrhythmias in left ventricular hypertrophy: the Framingham Heart Study. *Am J Cardiol* 1987;60:560-5.
156. Bikkina M, Larson MG, Levy D. Asymptomatic ventricular arrhythmias and mortality risk in subjects with left ventricular hypertrophy. *J Am Coll Cardiol* 1993;22:1111-6.
157. O'Kelly B, Browner WS, Massie B, et al. Ventricular arrhythmias in patients undergoing noncardiac surgery: the Study of Perioperative Ischemia Research Group. *JAMA* 1992;268:217-21.
158. Huikuri HV, Yli-Mayry S, Korhonen UR, et al. Prevalence and prognostic significance of complex ventricular arrhythmias after coronary arterial bypass graft surgery. *Int J Cardiol* 1990;27:333-9.
159. Juul-Moller S, Hedblad B, Janzon L, et al. Increased occurrence of arrhythmias in men with ischaemic type ST-segment depression during long-term ECG recording: prognostic impact on ischaemic heart disease: results from the prospective population study 'Men born in 1914,' Malmo, Sweden. *J Intern Med* 1991;230:143-9.
160. Gheno G, Mazzei G. Prognostic value of Holter monitoring in asymptomatic elderly subjects with sinus rhythm. *J Electrocardiol* 1996;29:39-44.
161. Martin A, Benbow LJ, Butrous GS, et al. Five-year follow-up of 101 elderly subjects by means of long-term ambulatory cardiac monitoring. *Eur Heart J* 1984;5:592-6.
162. Kennedy HL, Whitlock JA, Sprague MK, et al. Long-term follow-up of asymptomatic healthy subjects with frequent and complex ventricular ectopy. *N Engl J Med* 1985;312:193-7.
163. Bikkina M, Larson MG, Levy D. Prognostic implications of asymptomatic ventricular arrhythmias: the Framingham Heart Study. *Ann Intern Med* 1992;117:990-6.
164. Shih HT, Webb CR, Conway WA, et al. Frequency and significance of cardiac arrhythmias in chronic obstructive lung disease. *Chest* 1988;94:44-8.
165. Fabian TC, Cicala RS, Croce MA, et al. A prospective evaluation of myocardial contusion: correlation of significant arrhythmias and cardiac output with CPK-MB measurements. *J Trauma* 1991;31:653-60.
166. Zohar Y, Talmi YP, Frenkel H, et al. Cardiac function in obstructive sleep apnea patients following uvulopalatopharyngoplasty. *Otolaryngol Head Neck Surg* 1992;107:390-4.
167. Flemons WW, Remmers JE, Gillis AM. Sleep apnea and cardiac arrhythmias. Is there a relationship? *Am Rev Respir Dis* 1993;148:618-21.
168. Snisarenko AA. Cardiac rhythm in cats during physiological sleep in experimental myocardial infarction and beta-adrenergic receptor blockade. *Cor Vasa* 1986;28:306-14.
169. Molgaard H, Mickley H, Pless P, et al. Effects of metoprolol on heart rate variability in survivors of acute myocardial infarction. *Am J Cardiol* 1993;71:1357-9.
170. Filipecki A, Trusz-Gluzka M, Szydlo K, et al. Effect of propranolol and propafenone on heart rate variability in patients with ventricular arrhythmias (abstr). *Pacing Clin Electrophysiol* 1993;16:1157.
171. Bekheit S, Tangella M, el-Sakr A, et al. Use of heart rate spectral analysis to study the effects of calcium channel blockers on sympathetic activity after myocardial infarction. *Am Heart J* 1990;119:79-85.
172. Zuanetti G, Latini R, Neilson JM, et al. Heart rate variability in patients with ventricular arrhythmias: effect of antiarrhythmic drugs: Antiarrhythmic Drug Evaluation Group (ADEG). *J Am Coll Cardiol* 1991;17:604-12.
173. Hohnloser SH, Klingenhoben T, Zabel M, et al. Effect of sotalol on heart rate variability assessed by Holter monitoring in patients with ventricular arrhythmias: effect of sotalol on heart rate variability

- assessed by Holter monitoring in patients with ventricular arrhythmias. *Am J Cardiol* 1993;72:67A-71A.
174. Olson HG, Lyons KP, Troop P, et al. The high-risk acute myocardial infarction patient at 1-year follow-up: identification at hospital discharge by ambulatory electrocardiography and radionuclide ventriculography. *Am Heart J* 1984;107:358-66.
 175. Richards DA, Byth K, Ross DL, et al. What is the best predictor of spontaneous ventricular tachycardia and sudden death after myocardial infarction? *Circulation* 1991;83:756-63.
 176. Olona M, Candell-Riera J, Permanyer-Miralda G, et al. Strategies for prognostic assessment of uncomplicated first myocardial infarction: 5-year follow-up study. *J Am Coll Cardiol* 1995;25:815-22.
 177. Anderson JL, Gilbert EM, Alpert BL, et al. Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: a multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring: Flecainide Supraventricular Tachycardia Study Group. *Circulation* 1989;80:1557-70.
 178. Winkle RA, Peters F, Hall R. Characterization of ventricular tachyarrhythmias on ambulatory ECG recordings in post-myocardial infarction patients: arrhythmia detection and duration of recording, relationship between arrhythmia frequency and complexity, and day-to-day reproducibility. *Am Heart J* 1981;102:162-9.
 179. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effects of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. *Am J Cardiol* 1988;61:501-9.
 180. Reiter MJ, Karagounis LA, Mann DE, et al. Reproducibility of drug efficacy predictions by Holter monitoring in the electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial: ESVEM Investigators. *Am J Cardiol* 1997;79:315-22.
 181. Anastasiou-Nana MI, Gilbert EM, Miller RH, et al. Usefulness of d,l sotalol for suppression of chronic ventricular arrhythmias. *Am J Cardiol* 1991;67:511-6.
 182. Kennedy HL. Noncardiac adverse events and organ toxicity of moricizine during short- and long-term studies. *Am J Cardiol* 1990;65:47D-50D.
 183. Schmidt G, Ulm K, Barthel P. Variability of ventricular premature contractions (letter). *Circulation* 1989;79:1149-51.
 184. Anderson JL, Anastasiou-Nana MI, Menlove RL, et al. Spontaneous variability in ventricular ectopic activity during chronic antiarrhythmic therapy. *Circulation* 1990;82:830-40.
 185. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. *N Engl J Med* 1989;321:406-12.
 186. Echt DS, Liebson PR, Mitchell LB, et al. Mortality and morbidity in patients receiving encainide, flecainide, or placebo: the Cardiac Arrhythmia Suppression Trial. *N Engl J Med* 1991;324:781-8.
 187. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction: the Cardiac Arrhythmia Suppression Trial II Investigators. *N Engl J Med* 1992;327:227-33.
 188. Epstein AE, Hallstrom AP, Rogers WJ, et al. Mortality following ventricular arrhythmia suppression by encainide, flecainide, and moricizine after myocardial infarction: the original design concept of the Cardiac Arrhythmia Suppression Trial (CAST). *JAMA* 1993;270:2451-5.
 189. Wyse DG, Hallstrom A, McBride R, et al. Events in the Cardiac Arrhythmia Suppression Trial (CAST): mortality in patients surviving open label titration but not randomized to double-blind therapy. *J Am Coll Cardiol* 1991;18:20-8.
 190. Hallstrom AP, Greene HL, Huther ML. The healthy responder phenomenon in non-randomized clinical trials. CAST Investigators. *Stat Med* 1991;10:1621-31.
 191. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction: an overview of results from randomized controlled trials. *JAMA* 1993;270:1589-95.
 192. Waldo AL, Camm AJ, deRuyter H, et al. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction: the SWORD Investigators: Survival With Oral d-Sotalol. *Lancet* 1996;348:7-12.
 193. Burkart F, Pfisterer M, Kiowski W, et al. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). *J Am Coll Cardiol* 1990;16:1711-8.
 194. Ceremuzynski L, Kleczar E, Krzeminska-Pakula M, et al. Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. *J Am Coll Cardiol* 1992;20:1056-62.
 195. Doval HC, Nul DR, Grancelli HO, et al. Randomised trial of low-dose amiodarone in severe congestive heart failure: Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). *Lancet* 1994;344:493-8.
 196. The CASCADE Investigators. Randomized drug therapy in survivors of cardiac arrest (the CASCADE Study). *Am J Cardiol* 1993;72:280-7.
 197. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EMIAT, European Myocardial Infarct Amiodarone Trial Investigators. *Lancet* 1997;349:667-74.
 198. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia: Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. *N Engl J Med* 1995;333:77-82.
 199. Graboys TB, Lown B, Podrid PJ, et al. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs. *Am J Cardiol* 1982;50:437-43.
 200. Lampert S, Lown B, Graboys TB, et al. Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease. *Am J Cardiol* 1988;61:791-7.
 201. Mitchell LB, Duff HJ, Manyari DE, et al. A randomized clinical trial of the noninvasive and invasive approaches to drug therapy of ventricular tachycardia. *N Engl J Med* 1987;317:1681-7.
 202. Mason JW. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias: Electrophysiologic Study Versus Electrocardiographic Monitoring Investigators. *N Engl J Med* 1993;329:445-51.
 203. The Antiarrhythmics Versus Implantable Defibrillators (AVID) Investigators. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. *N Engl J Med* 1997;337:1576-83.
 204. Swerdlow CD, Peterson J. Prospective comparison of Holter monitoring and electrophysiologic study in patients with coronary artery disease and sustained ventricular tachyarrhythmias. *Am J Cardiol* 1985;56:577-80.
 205. Pritchett EL, Lee KL. Designing clinical trials for paroxysmal atrial tachycardia and other paroxysmal arrhythmias. *J Clin Epidemiol* 1988;41:851-8.
 206. Jung F, DiMarco JP. Antiarrhythmic drug therapy in the treatment of atrial fibrillation. *Cardiol Clin* 1996;14:507-20.
 207. Kennedy HL. Late proarrhythmia and understanding the time of occurrence of proarrhythmia. *Am J Cardiol* 1990;66:1139-43.
 208. Morganroth J, Pratt CM. Prevalence and characteristics of proarrhythmia from moricizine (Ethmozine). *Am J Cardiol* 1989;63:172-6.
 209. Wyse DG, Morganroth J, Ledingham R, et al. New insights into the definition and meaning of proarrhythmia during initiation of antiarrhythmic drug therapy from the Cardiac Arrhythmia Suppression Trial and its pilot study: the CAST and CAPS Investigators. *J Am Coll Cardiol* 1994;23:1130-40.
 210. Furman S, Hayes DL, Homes DR. Telemetry. In: A practice of cardiac pacing. 3rd ed. Mt Kisco, NY: Futura Publishing; 1993:633.
 211. Newman D, Dorian P, Downar E, et al. Use of telemetry function in the assessment of implanted antitachycardia device efficacy. *Am J Cardiol* 1992;70:616-21.
 212. Lascault G, Frank R, Himbert C, et al. Diagnosis of ventricular tachycardia using a pacemaker Holter function. *Pacing Clin Electrophysiol* 1994;17:1316-9.
 213. Levine PA, Sanders R, Rankowitz HT. Pacemaker diagnostics: measured data, event marker, electrogram, and event counter telemetry. In: Ellenbogen KA, Kay GN, Wilkoff BL, editors. Clinical cardiac pacing. Philadelphia, PA: WB Saunders Co; 1995:639-55.
 214. Ben-Zur U, Platt SB, Gross JN, et al. Direct and telemetered lead impedance. *Pacing Clin Electrophysiol* 1994;17:2004-7.
 215. Schuchert A, Cappato R, Kuck KH, et al. Reliability and variability of impedance measured by real-time telemetry. *Pacing Clin Electrophysiol* 1996;19:265-71.
 216. Dreifus LS, Fisch C, Griffin JC, et al. Guidelines for implantation of

- cardiac pacemakers and antiarrhythmia devices: a report of the American College of Cardiology/American Heart Association Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pacemaker Implantation). *J Am Coll Cardiol* 1991;18:1-13.
217. Janosik DL, Redd RM, Buckingham TA, et al. Utility of ambulatory electrocardiography in detecting pacemaker dysfunction in the early postimplantation period. *Am J Cardiol* 1987;60:1030-5.
218. Begemann MJ, Boute W. Heart rate monitoring in implanted pacemakers. *Pacing Clin Electrophysiol* 1988;11:1687-92.
219. Nowak B, Middeldorf T, Housworth CM, et al. Holter recordings with continuous marker annotations: a new tool in pacemaker diagnostics. *Pacing Clin Electrophysiol* 1996;19:1791-5.
220. Reiter MJ, Fain ES, Senelly KM, et al. Predictors of device activation for ventricular arrhythmias and survival in patients with implantable pacemakers/defibrillators: CADENCE Investigators. *Pacing Clin Electrophysiol* 1994;17:1487-98.
221. Birgersdotter-Green U, Rosenqvist M, Lindemans FW, et al. Holter documented sudden death in a patient with an implanted defibrillator. *Pacing Clin Electrophysiol* 1992;15:1008-14.
222. Callans DJ, Hook BG, Kleiman RB, et al. Unique sensing errors in third-generation implantable cardioverter-defibrillators. *J Am Coll Cardiol* 1993;22:1135-40.
223. Krahn AD, Klein GJ, Yee R, et al. Use of an extended monitoring strategy in patients with problematic syncope. *Circulation* 1999;99:406-10.
224. Mugica J, Thorner H. An experimental implantable "Holter." In: Feruglio G, editor. *Cardiac pacing: electrophysiology and pacemaker technology*. Padova, Italy: Piccin Medical Books; 1991:1311-4.
225. Crawford MH, Mendoza CA, O'Rourke RA, et al. Limitations of continuous ambulatory electrocardiogram monitoring for detecting coronary artery disease. *Ann Intern Med* 1978;89:1-5.
226. Schang SJ, Pepine CJ. Transient asymptomatic S-T segment depression during daily activity. *Am J Cardiol* 1977;39:396-402.
227. Deedwania PC, Carbajal EV. Silent myocardial ischemia: a clinical perspective. *Arch Intern Med* 1991;151:2373-82.
228. Deedwania PC, Carbajal EV. Prevalence and patterns of silent myocardial ischemia during daily life in stable angina patients receiving conventional antianginal drug therapy. *Am J Cardiol* 1990;65:1090-6.
229. Cohn PF. Silent myocardial ischemia: dimensions of the problem in patients with and without angina. *Am J Med* 1986;80:3-8.
230. Gottlieb SO, Weisfeldt ML, Ouyang P, et al. Silent ischemia as a marker for early unfavorable outcomes in patients with unstable angina. *N Engl J Med* 1986;314:1214-9.
231. Rocco MB, Nabel EG, Campbell S, et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring in patients with stable coronary artery disease. *Circulation* 1988;78:877-84.
232. Deedwania PC, Carbajal EV. Silent ischemia during daily life is an independent predictor of mortality in stable angina. *Circulation* 1990;81:748-56.
233. Tzivoni D, Gavish A, Zin D, et al. Prognostic significance of ischemic episodes in patients with previous myocardial infarction. *Am J Cardiol* 1988;62:661-4.
234. Raby KE, Goldman L, Cook EF, et al. Long-term prognosis of myocardial ischemia detected by Holter monitoring in peripheral vascular disease. *Am J Cardiol* 1990;66:1309-13.
235. de Marchena E, Asch J, Martinez J, et al. Usefulness of persistent silent myocardial ischemia in predicting a high cardiac event rate in men with medically controlled, stable angina pectoris. *Am J Cardiol* 1994;73:390-2.
236. Yeung AC, Barry J, Orav J, et al. Effects of asymptomatic ischemia on long-term prognosis in chronic stable coronary disease. *Circulation* 1991;83:1598-604.
237. Deedwania PC, Carbajal EV. Usefulness of ambulatory silent myocardial ischemia added to the prognostic value of exercise test parameters in predicting risk of cardiac death in patients with stable angina pectoris and exercise-induced myocardial ischemia. *Am J Cardiol* 1991;68:1279-86.
238. Madjlissi-Simon T, Mary-Krause M, et al. Persistent transient myocardial ischemia despite beta-adrenergic blockade predicts a higher risk of adverse cardiac events in patients with coronary artery disease. *J Am Coll Cardiol* 1996;27:1586-91.
239. Currie P, Ashby D, Saltissi S. Prognostic significance of transient myocardial ischemia on ambulatory monitoring after acute myocardial infarction. *Am J Cardiol* 1993;71:773-7.
240. Gottlieb SO, Gottlieb SH, Achuff SC, et al. Silent ischemia on Holter monitoring predicts mortality in high-risk postinfarction patients. *JAMA* 1988;259:1030-5.
241. Deedwania PC. Asymptomatic ischemia during predischARGE Holter monitoring predicts poor prognosis in the postinfarction period. *Am J Cardiol* 1993;71:859-61.
242. Gill JB, Cairns JA, Roberts RS, et al. Prognostic importance of myocardial ischemia detected by ambulatory monitoring early after acute myocardial infarction. *N Engl J Med* 1996;334:65-70.
243. Mulcahy D, Keegan J, Sparrow J, et al. Ischemia in the ambulatory setting: the total ischemic burden: relation to exercise testing and investigative and therapeutic implications. *J Am Coll Cardiol* 1989;14:1166-72.
244. Deedwania PC, Carbajal EV. Exercise test predictors of ambulatory silent ischemia during daily life in stable angina pectoris. *Am J Cardiol* 1990;66:1151-6.
245. Krantz DS, Helmers KF, Bairey CN, et al. Cardiovascular reactivity and mental stress-induced myocardial ischemia in patients with coronary artery disease. *Psychosom Med* 1991;53:1-12.
246. Gabbay FH, Krantz DS, Kop WJ, et al. Triggers of myocardial ischemia during daily life in patients with coronary artery disease: physical and mental activities, anger and smoking. *J Am Coll Cardiol* 1996;27:585-92.
247. Sharaf BL, Williams DO, Miele NJ, et al. A detailed angiographic analysis of patients with ambulatory electrocardiographic ischemia: results from the Asymptomatic Cardiac Ischemia Pilot (ACIP) study angiographic core laboratory. *J Am Coll Cardiol* 1997;29:78-84.
248. Jiang W, Babyak M, Krantz DS, et al. Mental stress-induced myocardial ischemia and cardiac events. *JAMA* 1996;275:1651-6.
249. Pepine CJ, Sharaf B, Andrews TC, et al. Relation between clinical, angiographic, and ischemic findings at baseline and ischemia-related adverse outcomes at 1 year in the Asymptomatic Cardiac Ischemia Pilot Study. *J Am Coll Cardiol* 1997;29:1483-9.
250. Raby KE, Goldman L, Creager MA, et al. Correlation between preoperative ischemia and major cardiac events after peripheral vascular surgery. *N Engl J Med* 1989;321:1296-300.
251. Raby KE, Barry J, Creager MA, et al. Detection and significance of intraoperative and postoperative myocardial ischemia in peripheral vascular surgery. *JAMA* 1992;268:222-7.
252. Mangano DT, Browner WS, Hollenberg M, et al. Association of perioperative myocardial ischemia with cardiac morbidity and mortality in men undergoing noncardiac surgery: the Study of Perioperative Ischemia Research Group. *N Engl J Med* 1990;323:1781-8.
253. Fleisher LA, Rosenbaum SH, Nelson AH, et al. The predictive value of preoperative silent ischemia for postoperative ischemic cardiac events in vascular and nonvascular surgery patients. *Am Heart J* 1991;122:980-6.
254. Kirwin JD, Ascer E, Gennaro M, et al. Silent myocardial ischemia is not predictive of myocardial infarction in peripheral vascular surgery patients. *Ann Vasc Surg* 1993;7:27-32.
255. McPhail NV, Ruddy TD, Barber GG, et al. Cardiac risk stratification using dipyridamole myocardial perfusion imaging and ambulatory ECG monitoring prior to vascular surgery. *Eur J Vasc Surg* 1993;7:151-5.
256. Pasternack PF, Grossi EA, Baumann FG, et al. The value of silent myocardial ischemia monitoring in the prediction of perioperative myocardial infarction in patients undergoing peripheral vascular surgery. *J Vasc Surg* 1989;10:617-25.
257. Fleisher LA, Rosenbaum SH, Nelson AH, et al. Preoperative dipyridamole thallium imaging and ambulatory electrocardiographic monitoring as a predictor of perioperative cardiac events and long-term outcome. *Anesthesiology* 1995;83:906-17.
258. Mangano DT, Goldman L. Preoperative assessment of patients with known or suspected coronary disease. *N Engl J Med* 1995;333:1750-6.
259. Mangano DT, Browner WS, Hollenberg M, et al. Long-term cardiac prognosis following noncardiac surgery: the Study of Perioperative Ischemia Research Group. *JAMA* 1992;268:233-9.
260. Patel DJ, Mulcahy D, Norrie J, et al. Natural variability of transient myocardial ischaemia during daily life: an obstacle when assessing efficacy of anti-ischaemic agents? *Heart* 1996;76:477-82.
261. Stone PH, Gibson RS, Glasser SP, et al. Comparison of propranolol,

- diltiazem, and nifedipine in the treatment of ambulatory ischemia in patients with stable angina. *Circulation* 1990;82:1962-72.
262. Deedwania PC, Carbajal EV, Nelson JR, et al. Anti-ischemic effects of atenolol versus nifedipine in patients with coronary artery disease and ambulatory silent ischemia. *J Am Coll Cardiol* 1991;17:963-9.
263. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring: Canadian Amlodipine/Atenolol in Silent Ischemia Study (CASIS) Investigators. *J Am Coll Cardiol* 1995;25:619-25.
264. Pepine CJ, Cohn PF, Deedwania PC, et al. Effects of treatment on outcome in mildly symptomatic patients with ischemia during daily life: the Atenolol Silent Ischemia Study (ASIST). *Circulation* 1994;90:762-8.
265. Knatterud GL, Bourassa MG, Pepine CJ, et al. Effects of treatment strategies to suppress ischemia in patients with coronary artery disease: 12-week results of the Asymptomatic Cardiac Ischemia Pilot (ACIP) study. *J Am Coll Cardiol* 1994;24:11-20.
266. Chaitman BR, Stone PH, Knatterud GL, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: impact of anti-ischemia therapy on the 12-week rest electrocardiogram and exercise test outcomes: the ACIP Investigators. *J Am Coll Cardiol* 1995;26:585-93.
267. Bourassa MG, Pepine CJ, Forman SA, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: effects of coronary angioplasty and coronary artery bypass graft surgery on recurrent angina and ischemia: the ACIP investigators. *J Am Coll Cardiol* 1995;26:606-14.
268. Rogers WJ, Bourassa MG, Andrews TC, et al. Asymptomatic Cardiac Ischemia Pilot (ACIP) study: outcome at 1 year for patients with asymptomatic cardiac ischemia randomized to medical therapy or revascularization: the ACIP Investigators. *J Am Coll Cardiol* 1995;26:594-605.
269. Dargie HJ, Ford I, Fox KM. Total Ischaemic Burden European Trial (TIBET): effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina: the TIBET Study Group. *Eur Heart J* 1996;17:104-12.
270. Von Arnim T. Prognostic significance of transient ischemic episodes: response to treatment shows improved prognosis: results of the Total Ischemic Burden Bisoprolol Study (TIBBs) follow-up. *J Am Coll Cardiol* 1996;28:20-4.
271. Stone PH, Chaitman BR, Forman S. Prognostic significance of myocardial ischemia detected by ambulatory electrocardiography, exercise treadmill testing, and electrocardiogram at rest to predict cardiac events by 1 year (the Asymptomatic Cardiac Ischemia Pilot [ACIP] study). *Am J Cardiol* 1997;80:1395-401.
272. Dick M II, McFadden D, Crowley D, et al. Diagnosis and management of cardiac rhythm disorders by transtelephonic electrocardiography in infants and children. *J Pediatr* 1979;94:612-5.
273. Fyfe DA, Holmes DR, Neubauer SA, et al. Transtelephonic monitoring in pediatric patients with clinically suspected arrhythmias. *Clin Pediatr* 1984;23:139-43.
274. Porter CJ, Gillette PC, McNamara DG. Twenty-four-hour ambulatory ECGs in the detection and management of cardiac arrhythmias in infants and children. *Pediatr Cardiol* 1980;1:203-8.
275. Goldstein MA, Hesslein P, Dunnigan A. Efficacy of transtelephonic electrocardiographic monitoring in pediatric patients. *Am J Dis Child* 1990;144:178-82.
276. Karpawich PP, Cavitt DL, Sugalski JS. Ambulatory arrhythmia screening in symptomatic children and young adults: comparative effectiveness of Holter and telephone event recordings. *Pediatr Cardiol* 1993;14:147-50.
277. Houyel L, Fournier A, Centazzo S, et al. Use of transtelephonic electrocardiographic monitoring in children with suspected arrhythmias. *Can J Cardiol* 1992;8:741-4.
278. Driscoll DJ, Jacobsen SJ, Porter CJ, et al. Syncope in children and adolescents. *J Am Coll Cardiol* 1997;29:1039-45.
279. Zimetbaum P, Kim KY, Ho KK, et al. Utility of patient-activated cardiac event recorders in general clinical practice. *Am J Cardiol* 1997;79:371-2.
280. Seliem MA, Benson DW, Strasburger JF, et al. Complex ventricular ectopic activity in patients less than 20 years of age with or without syncope, and the role of ventricular extrastimulus testing. *Am J Cardiol* 1991;68:745-50.
281. Selbst SM, Ruddy RM, Clark BJ, et al. Pediatric chest pain: a prospective study. *Pediatrics* 1988;82:319-23.
282. Kaden GG, Shenker IR, Gootman N. Chest pain in adolescents. *J Adolesc Health* 1991;12:251-5.
283. Wolfe RR, Driscoll DJ, Gersony WM, et al. Arrhythmias in patients with valvar aortic stenosis, valvar pulmonary stenosis, and ventricular septal defect: results of 24-hour ECG monitoring. *Circulation* 1993;87 Suppl I:I89-I101.
284. Garson A Jr, Bink-Boelkens M, Hesslein PS, et al. Atrial flutter in the young: a collaborative study of 380 cases. *J Am Coll Cardiol* 1985;6:871-8.
285. Cullen S, Celermajer DS, Franklin RC, et al. Prognostic significance of ventricular arrhythmia after repair of tetralogy of Fallot: a 12-year prospective study. *J Am Coll Cardiol* 1994;23:1151-5.
286. Chandar JS, Wolff GS, Garson A Jr, et al. Ventricular arrhythmias in postoperative tetralogy of Fallot. *Am J Cardiol* 1990;65:655-61.
287. Garson A Jr. Ventricular arrhythmia after repair of congenital heart disease: who needs treatment? *Cardiol Young* 1991;1:177-81.
288. Paul T, Marchal C, Garson A Jr. Ventricular couplets in the young: prognosis related to underlying substrate. *Am Heart J* 1990;119:577-82.
289. McKenna WJ, Franklin RC, Nihoyannopoulos P, et al. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. *J Am Coll Cardiol* 1988;11:147-53.
290. Garson A Jr, Dick M II, Fournier A, et al. The long QT syndrome in children: an international study of 287 patients. *Circulation* 1993;87:1866-72.
291. Christiansen JL, Guccione P, Garson A Jr. Difference in QT interval measurement on ambulatory ECG compared with standard ECG. *Pacing Clin Electrophysiol* 1996;19:1296-1303.
292. Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. *N Engl J Med* 1987;316:835-9.
293. Zardini M, Yee R, Thakur RK, et al. Risk of sudden arrhythmic death in the Wolff-Parkinson-White syndrome: current perspectives. *Pacing Clin Electrophysiol* 1994;17:966-75.
294. Silka MJ, Kron J, Walence CG, et al. Assessment and follow-up of pediatric survivors of sudden cardiac death. *Circulation* 1990;82:341-9.
295. Joint Steering Committees of the Unexplained Cardiac Arrest Registry and of the Idiopathic Ventricular Fibrillation Registry of the United States. Survivors of out-of-hospital cardiac arrest with apparently normal heart: need for definition and standardized clinical evaluation: Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. *Circulation* 1997;95:265-72.
296. Yanagisawa A, Miyagawa M, Yotsukura M, et al. The prevalence and prognostic significance of arrhythmias in Duchenne type muscular dystrophy. *Am Heart J* 1992;124:1244-50.
297. Melacini P, Fanin M, Danieli GA, et al. Cardiac involvement in Becker muscular dystrophy. *J Am Coll Cardiol* 1993;22:1927-34.
298. Fragola PV, Luzi M, Calo L, et al. Cardiac involvement in myotonic dystrophy. *Am J Cardiol* 1994;74:1070-2.
299. Larsen RL, Jakacki RI, Vetter VL, et al. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. *Am J Cardiol* 1992;70:73-7.
300. Pfammatter JP, Paul T, Lehmann C, et al. Efficacy and proarrhythmia of oral sotalol in pediatric patients. *J Am Coll Cardiol* 1995;26:1002-7.
301. Garson A Jr. Dosing the newer antiarrhythmic drugs in children: considerations in pediatric pharmacology. *Am J Cardiol* 1986;57:1405-7.
302. Krongrad E. Prognosis for patients with congenital heart disease and postoperative intraventricular conduction defects. *Circulation* 1978;57:867-70.
303. Fenelon G, d'Avila A, Malacky T, et al. Prognostic significance of transient complete atrioventricular block during radiofrequency ablation of atrioventricular node reentrant tachycardia. *Am J Cardiol* 1995;75:698-702.
304. Packer DL, Bardy GH, Worley SJ, et al. Tachycardia-induced cardiomyopathy: a reversible form of left ventricular dysfunction. *Am J Cardiol* 1986;57:563-70.

Subject Index

A

ACC, staff, 939
ACC/AHA committee membership, 914
ACC/AHA Guidelines for Ambulatory Electrocardiography (AECG), 913
ACC/AHA Task Force on Practice Guidelines, 913
Age factors. *See also* Elderly
 ambulatory electrocardiography for syncope and, 921
AHA. *See also* ACC/AHA staff, 939
Ambulatory electrocardiography, equipment. *See* Equipment
American College of Cardiology. *See* ACC
American Heart Association. *See* AHA
American National Standard, 915
Amiodarone, effect on mortality rates, 930
 after myocardial infarction, 924
Amplitude-modulation (AM) systems, 915
Analog format, signals recorded in, 917
Angina pectoris, ischemia during ambulatory electrocardiography in, 933
Anginal syndrome, evaluation of, 933
Antiarrhythmic therapy, efficacy of, ambulatory electrocardiographic monitoring of, 929-931
Antidepressants, 917
Anti-ischemic therapy, efficacy of, evaluation of, 933, 935, 936t
Arrhythmia. *See also* specific arrhythmia
 ambulatory electrocardiographic monitoring of, efficacy of, 934t
 analysis of, 917
 assessment of patients at risk for, 922, 929
 in congestive heart failure, 924, 928
 in diabetic neuropathy, 928
 in hemodialysis patients, 928
 in hypertrophic cardiomyopathy, 924, 928
 indications for, 929
 monitoring pharmacologic management, 929
 after myocardial infarction, 922-924, 925t, 926t-927t
 in preoperative and postoperative patients, 928-929
 in systemic hypertension, 928
 in valvular heart disease, 928
 asymptomatic, 920
 assessment of therapy for, 931
 frequency and type of
 reduction in, 916
 variability of, 916, 930, 934t
 in heart rate variability, 919
 supraventricular
 guidelines for assessing therapy for, 931
 therapy of, monitoring of, 930
 symptomatic, assessment of, 920
 traditional use of ambulatory electrocardiography for, 913
 transient, 920
 ventricular, 924. *See also* specific arrhythmia
 in hypertrophic cardiomyopathy, 924
 ICD for, assessment of, 932
"Arrhythmia-free interval," 931
Artifacts
 in analysis of heart rate variability, 919
 distortion of ST-segment, 915
 minimization of, 917
 motion, 917

ATRAMI (Autonomic Tone and Reflexes after Myocardial Infarction) study, 923-924
Atrial ectopy, 930
Atrioventricular (AV) block, congenital, 938
Atrioventricular (AV) conduction, abnormalities, 931
Atrioventricular (AV) delay, 932
Atrioventricular (AV) node blocking drugs, effects of, monitoring of, 930
Atrium, pacing thresholds in, 932
Autonomic Tone and Reflexes after Myocardial Infarction study. *See* ATRAMI

B

Baroreflex sensitivity (BRS), after myocardial infarction, 923
Baseline wander, 917
Bipolar lead configurations, 916
Bradycardia, in pediatric patients, 937

C

Cardiac Arrhythmia Suppression Trial. *See* CAST
Cardiac events, undersensing or oversensing of, 932
Cardiomyopathy. *See also* Hypertrophy dilated, 924
 in pediatric patients, ambulatory electrocardiographic monitoring of, 937
 hypertrophic, 937
 arrhythmias in patients with, ambulatory electrocardiographic assessment of, 924, 928
 in pediatric patients, ambulatory electrocardiographic monitoring of, 937
Cardiovascular disease, evaluation of pediatric patients with, 937-938
Cardioverter-defibrillator, implantable (ICD), 921, 931
 effect on mortality rates, 924
 function, assessment of, 931-932
 recording capabilities associated with, 917
CAST (Cardiac Arrhythmia Suppression Trial), 930, 931
Catheter ablation, radiofrequency, 938
Cerebrovascular accident, 920
Chest pain, 930
 in pediatric patients, 936, 937
Class I conditions
 assessment of antiarrhythmic therapy, indications for ambulatory electrocardiography for, 931
 pacemaker and ICD function in, indications for ambulatory electrocardiography to assess, 932
 patients without symptoms of arrhythmia, ambulatory electrocardiographic arrhythmia detection to assess risk for future cardiac events, 929
 in pediatric patients, indications for ambulatory electrocardiographic monitoring in, 938
 symptoms related to rhythm disturbances, indications for ambulatory electrocardiography in, 921
 usefulness of ambulatory electrocardiography in, 914
Class II conditions
 usefulness of ambulatory electrocardiography in, 914
Class IIa conditions
 assessment of antiarrhythmic therapy, indications for ambulatory electrocardiography for, 931

ischemia monitoring, indications for ambulatory electrocardiography for, 936
in pediatric patients, indications for ambulatory electrocardiographic monitoring in, 938
usefulness of ambulatory electrocardiography in, 914
Class IIb conditions
 assessment of antiarrhythmic therapy, indications for ambulatory electrocardiography for, 931
 ischemia monitoring, indications for ambulatory electrocardiography for, 936
 pacemaker and ICD function in, indications for ambulatory electrocardiography to assess, 932
 patients without symptoms of arrhythmia
 ambulatory electrocardiographic arrhythmia detection to assess risk for future cardiac events, 929
 ambulatory electrocardiographic heart rate variability detection to assess risk for future cardiac events, 929
 in pediatric patients, indications for ambulatory electrocardiographic monitoring in, 938
 symptoms related to rhythm disturbances, indications for ambulatory electrocardiography in, 921, 922
 usefulness of ambulatory electrocardiography in, 914
Class III conditions
 ischemia monitoring, indications for ambulatory electrocardiography for, 936
 pacemaker and ICD function in, indications for ambulatory electrocardiography to assess, 932
 patients without symptoms of arrhythmia
 ambulatory electrocardiographic arrhythmia detection to assess risk for future cardiac events, 929
 ambulatory electrocardiographic heart rate variability detection to assess risk for future cardiac events, 929
 in pediatric patients, indications for ambulatory electrocardiographic monitoring in, 938
 symptoms related to rhythm disturbances, indications for ambulatory electrocardiography in, 922
 usefulness of ambulatory electrocardiography in, 914
Clinical outcome, of myocardial ischemia detected by ambulatory electrocardiography, 933, 936t
Congenital heart defects. *See also* Pediatric patients
 ambulatory electrocardiographic monitoring of, 937
Congestive heart failure. *See* Heart failure
Consciousness, loss of, 914, 920
Continuous recorders, recording
 description of, 915-916
 indications for, 920
 uses of, 914
Contractions. *See* Ventricular contractions
Conventional format for recording, 915. *See also* Continuous recorders
Coronary artery disease (CAD), 932
 stable
 incidence and prognostic significance of, studies defining, 935t
 myocardial ischemia detected by ambulatory electrocardiography in, 933

D

Daily activities, routine recordings during, 917
Data transfer, electronic, 915
Decision making, use of ambulatory electrocardiography for, 914
Depolarization, ventricular premature, 931
Diabetic neuropathy, heart rate variability in, ambulatory electrocardiographic monitoring for, 928
Diagnostic accuracy, 914
Dialysis patients. *See* Hemodialysis patients
Diaphoresis, 921
Digital format, recording of signal in, 915
Digitization, rate of, 919
Digoxin, 917
Distribution-based artifact in heart rate variability determination, 919
Dizziness, 937
vertigo distinguished from, 920

E

Ectopic beats. *See also* Atrial ectopy; Ventricular ectopy
number of, calculation of, 917
Ejection fraction, 924
Elderly. *See also* Age factors
Elderly, screening of, 929
Electrode preparation, method of, 916
Electrophysiologic studies, ambulatory electrocardiography compared with, 930
Encainide, effect on mortality rates, 930
Equipment, ambulatory electrocardiography, 914-915
AECG recording capabilities associated with pacemakers and ICDs, 917
continuous recorders, 915-916
electrode preparation and lead systems, 916
emerging technologies, 918
intermittent recorders, 916
playback systems and methods of analysis, 917-918
technical capacity of, 914
variability of arrhythmias and ischemia and optimal duration of recording, 916
European Society of Cardiology (ESC), Task Force of, 918, 919
Event recorders, 914. *See also* Intermittent recorders
activation of, 920, 916
long-term, 913
patient-activated, 915
uses of, 914-915
Exercise testing, 916
ischemic response during, 933

F

Facsimile, 917
False-positive changes, 935
Fibrillation. *See* Ventricular fibrillation
Flash cards, 915
Flecainide, effect on mortality rates, 930
Fourier transformation, 918
Frequency domain measures of heart rate variability, 919t
Frequency-modulated (FM) systems, 915
"Full disclosure," 915
lack of, 915

G

Gender, ambulatory electrocardiography for syncope and, 921

H

Hard drive
miniature, 915-916
portable, 915
"Healthy responder," 930
Heart failure, arrhythmias in patients with, ambulatory electrocardiographic assessment of, 924, 928t
Heart rate variability (HRV), 929
analysis of, 913
arrhythmia after myocardial infarction and, assessment for, 923, 924t
components of, 918t
in congestive heart failure, 924, 928t
day-to-day variability, 919-920
in diabetic neuropathy, 928
general considerations, 918
in hypertrophic cardiomyopathy, 924
multiple markers for, 923
technical requirements for recording and analysis, 918-919
triangular index, 923
in valvular heart disease, 928
Heart rhythm, symptoms related to, assessment of indications for ambulatory electrocardiography for, 921-922
selection of recording techniques, 920-921
specific symptoms, 921, 922t
symptomatic arrhythmias, 920
Hemodialysis patients, arrhythmias in, ambulatory electrocardiographic monitoring for, 928
High-risk patients, in myocardial ischemia, identification of, 933
Hypertension, systemic, arrhythmias in, ambulatory electrocardiographic monitoring for, 928
Hypertrophy. *See also* Cardiomyopathy
left ventricular, in systemic hypertension, 928

I

ICD. *See* Cardioverter-defibrillator, implantable
In-hospital monitoring, continuous, in pediatric patients with cardiovascular disease, 938
Intermittent recorders
description of, 916
event recorders, 914-915. *See also* Event recorders
indications for, 920, 921
loop recorders, 914. *See also* Loop recorders
for syncope, 921
uses of, 914
Internet, 917
Interobserver-intraobserver agreement, 917
Ischemia. *See also* Anti-ischemic therapy; Myocardial ischemia
ambulatory electrocardiographic monitoring for, 916
analysis of, 917-918
asymptomatic, assessment of, 913
frequency of, variability of, 916
identification of, 917
Isoelectric reference point, 917

J

J-point, 917

L

Late potentials, arrhythmia after myocardial infarction and, 923
Lead systems, types of, 916
Left ventricular function, 929
Loop recorders, 914, 916
activation of, 914
Loss-less compression method, 915
"Lossy" compression, 915
Lung disease, obstructive, 929

M

MADIT (Multicenter Automatic Defibrillator Implantation Trial), 924
Malignancy, childhood, 938
Modem, 917
Monitors, ambulatory electrocardiography, self-activation of, 913
Morizine, effect on mortality rates, 930
Mortality rates, effect of antiarrhythmic drug therapy on, 930
Motion-related artifacts, in heart rate variability determination, 919
MSSD, 920
Multicenter Automatic Defibrillator Implantation Trial. *See* MADIT
Muscular dystrophy, Duchenne or Becker, 938
Myocardial infarction
arrhythmia development after
assessment of risk for, 922-924, 925t, 926t-927t
sensitivity and specificity of noninvasive tests for predicting, 923, 925t
prognosis after, in patients undergoing 24 hour ambulatory electrocardiography, predicting of, 926t-927t
recent, myocardial ischemia in, 933
Myocardial ischemia
ambulatory electrocardiographic monitoring for, 932-933
limitations, 935
prevalence and predictive value, 933
role in therapeutic evaluation, 933, 935, 936t
false-positive changes, 935
transmural, 935
Myotonic dystrophies, 938

N

Near-syncope, in pediatric patients, 936, 937
Nehb J lead, inverse, 916
Neurologic symptoms, transient, in pediatric patients, 937
Neuropathy. *See* Diabetic neuropathy
"Noise"
baseline, 915
in R wave timing, 919
Normal populations, heart rate variability in, 919
North American Society of Pacing and Electrophysiology (NASPE), 918, 919

O

On-line interpretations, accuracy of, 915
Overreading, 917

P

P-R segment, 917
Pacemaker, 921
function, assessment of, 931-932
in pediatric patients, monitoring of, 938
recording capabilities associated with, 917
Pacemaker activity, recording of, 916
Page-type displays, 917
Palpitations, 920
ambulatory electrocardiography for, 921, 922t
in pediatric patients, 936, 937t
Parasympathetic tone, 918
Pediatric patients. *See also* Congenital heart defects; Surgery, pediatric
Pediatric patients, purpose of ambulatory electrocardiographic monitoring in, 936, 938
evaluation after therapy or intervention, 938
evaluation of patient with known cardiovascular disease, 937-938
evaluation of symptoms, 936-937

indications, 938
Pharmacological management, monitoring of, 929
Playback systems, 917
 rapid, 917
 tape, 917
pNN50, 920, 923
Postoperative patients, arrhythmias in, ambulatory electrocardiographic monitoring for, 928-929
PPV, 923
Preexcitation syndrome, 938
Preoperative evaluation, of patients with peripheral vascular disease, ambulatory electrocardiography for, 933, 936t
Preoperative patients, arrhythmias in, ambulatory electrocardiographic monitoring for, 928-929
Proarrhythmia
 concept of, 931
 detection of, 931
Prolonged monitoring, 935

Q

Q wave, ischemia detection by, 917
QRS morphology, distortion of, 917
QRS-T complex
 "lossy" compression of, 915
 on-line analysis of, 915
QRS-T morphology, 914
 for ischemia identification, 917
QT interval
 dispersion, 918
 increased, in proarrhythmia, 931
 long QT syndrome, 937

R

R-R interval, 919
 height of, histogram of, 918
R-R variability. *See also* Heart rate variability
 analysis of, 918
 monitoring of, in pharmacologic treatment, 929
R-wave, 917
 peak identification, temporal accuracy of, 919
 timing
 errors in, 919
Rate responsiveness, 932
Recorders, AECG, 921
 continuous. *See* Continuous recorders
 intermittent. *See* Intermittent recorders
Recording
 duration of, 918
 optimal duration of, 916

 of patient symptoms, technique for, 920-921
Repolarization, abnormalities, 935
rMSSD, 918, 923

S

SDANN (standard deviation of the averaged normal sinus R-R intervals), 918
SDNN (standard deviation of all normal sinus R-R intervals), 918, 920, 923
Shortness of breath, 921
Signal, recording of, 915
Signal averaging, 915, 918, 923, 929
Sinus rhythm, 917
Skin, preparation for electrode placement, 916
Skin resistance, 916
Solid-state format, limitations of, 915
Solid-state recording devices, 915
Spectral analysis
 of heart rate variability, 918
 high-frequency (H-F) component of, 918
 low-frequency (L-F) component of, 918
Spectral component, of heart rate variability, 918t
ST-segment
 artifactual distortion of, 915
 changes, 916
 causes of, 935
 in myocardial ischemia, 933
 deviation, 914
 analysis of, 913
 distortion of, 917
 duration, variability in, 916
 elevation, 935
 interpretation, differences in, 917
 in ischemia analysis, 917-918
Standard deviation of the all normal sinus R-R intervals. *See* SDNN
Standard deviation of the averaged normal sinus R-R intervals. *See* SDANN
Storage capacity, problems of, 915
Storage methods, 915
 compressed, 915
Stress, mental, 933
Sudden death
 in hypertrophic cardiomyopathy, 924
 in pediatric patients, 937
 risk for, 922
Superimposition scanning, 917
 for ischemia analysis, 917
Supraventricular tachycardia, in pediatric patients, 937
Surgery
 pediatric, 938

 for congenital heart disease, ambulatory electrocardiographic monitoring of, 937
 vascular, preoperative evaluation for, ambulatory electrocardiography for, 933, 936t
Symptoms, lack of, 933
Syncope, 920. *See also* Near-syncope
 ambulatory electrocardiography for, 921
 monitoring of, yield of AECG for, 921, 921T
 in pediatric patients, 936, 937

T

T wave, 917
 polarity and morphology, 935
T wave alternans, 915, 918
Tachycardia. *See* Ventricular tachycardia
Test cable, 916
Time-domain parameters, 918
 for arrhythmia risk analysis after myocardial infarction, 923
 of heart rate variability, 918t

V

V₃ (CM₃), 916
V₅ (CM₅), 916
Valve disease, arrhythmias in, ambulatory electrocardiographic monitoring for, 928
Ventricle, pacing thresholds in, 932
Ventricular contractions, premature, in myocardial infarction patients, 922
Ventricular ectopy
 antiarrhythmic drug therapy for, 930
 frequency of, determination of, 932
 after myocardial infarction, 922
 predictive value of, 922, 923
 in pediatric patients, 937
 therapy for, efficacy of ambulatory electrocardiographic monitoring, 929-930
 in valvular heart disease, 928
Ventricular fibrillation, 924
Ventricular function, 923
Ventricular tachycardia, 924
 drug therapy for, assessment of, 930
 nonsustained, 920
Vertigo, distinguished from dizziness, 920

W

Wolff-Parkinson-White syndrome, 938
Writing groups, 913